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Biotherapeutics, an emerging class of medicines containing biopolymers (e.g., 
proteins, peptide, and polysaccharides) have been developed for a variety of indications 
including cancer, autoimmune, genetic, and blood diseases. Among these biopolymers 
protein therapeutics have been the rapidly growing segment in the pharmaceutical 
industry. This trend combined with the complexity of proteins has necessitated the 
development of powerful and robust analytical methods to study their structure and 
interactions with physiological partners. 
Mass spectrometry (MS) has become an indispensable tool to analyze various 
attributes of protein drugs such as profiling of intact mass, amino acid sequencing, and 
post translational modifications (PTMs).  In this work novel analytical methods have 
been developed by combining non-denaturing chromatographic separations (such as 
 
viii 
size exclusion chromatography and ion exchange chromatography) with native ESI MS. 
In addition to providing information of mass and non-covalent assemblies, native ESI MS 
has an advantage of probing conformational integrity of proteins by analyzing ionic 
charge state distributions in the mass spectrum.  
Size exclusion chromatography with online native ESI MS detection method 
developed in this work allowed characterization of higher order structure of proteins 
and probe aggregation propensity. Using the same SEC/native ESI MS workflow a 
method to find kinetics and equilibrium binding constant of transient protein 
interactions have also been developed. Combination of ion exchange chromatography 
(IXC) with native ESI MS and MS/MS detection was developed and shown to be effective 
in characterization of positional isomers of protein conjugates and PTMs of a 
biotherapeutic recombinant human interferon beta 1a. To characterize highly 
heterogeneous PEGylated glycoprotein (conjugated with a 20kDa PEG) analytical 
methods using IXC/native ESI MS combined with limited charge reduction and collisional 
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1.1. Biopolymers as pharmaceuticals 
Biotherapeutics, also known as biologics are a class of medicines containing 
biopolymers (e.g., proteins, peptides, polysaccharides, and nucleic acids) either 
extracted from biological sources or derived by recombinant DNA technology.1-4 Among 
the many biopolymers, protein based therapeutics represent the majority of 
biotherapeutics, and in the past few years has seen a rapid growth with now over 212 
products approved for the treatment of a variety of chronic and life-threatening 
disorders ranging from cancer, metabolic, autoimmune to genetic diseases.5, 6  The main 
advantage of biotherapeutics over small molecule drugs is their ability to bind their 
physiological target in vivo with high specificity resulting in high potency with fewer side 
effects.1 However, owing to large size and complexity of biotherapeutics compared to 
small molecule drugs; biotherapeutics tend to be highly heterogeneous due to various 
modifications that can happen during expression or upon storage or stress. These 
modifications inevitably affect the activity and safety profile of biotherapeutics thus 
validating the need of strong and robust analytical methods to characterize them.  
1.1.1. Protein based therapeutics 
Protein therapeutics constitute a broad type of biological products, which 
include recombinant enzymes, monoclonal antibodies, hormones, growth factors, fusion 
proteins, cytokines, and blood factors.1 This class of therapeutics usually works by 
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controlling immune system, decreasing the inflammatory response, or modulating 
various metabolic processes.  
To enhance the existing pharmacokinetic profile of protein therapeutics and to 
expand the therapeutic activity many strategies have been incorporated resulting in the 
development of the so-called second generation protein therapeutics. The notable 
strategies among these are genetically engineering the glycosylation pattern7 or fusing 
proteins with Fc region of antibody to increase serum half-life8, covalent surface 
attachment of polyethylene glycols (PEG) to decrease renal clearance,9 and chemical 
modification of protein with drug payload for site specific activity.10  
1.1.2. Peptide based therapeutics 
Peptide therapeutics are relatively smaller molecules containing fewer than 50 
amino acids.  Generally peptide molecules act selectively on various cell surface 
receptors such as G protein-coupled receptors.11 Though many peptide drugs have been 
approved, the development of peptide therapeutic is more often hindered due to poor 
chemical and physical stability, and lack of adequate plasma half-life.2 To overcome 
these limitations various chemical strategies such as incorporating specific amino acids, 
introducing salt bridges or disulfide bonds to increase solubility and stability are being 
researched.12, 13 
1.1.3. Polysaccharide based therapeutics (heparin based medicines) 
Heparin is a negatively charge linear polysaccharide belonging to the family of 
molecules known as glycosaminoglycans.14 Due to involvement of heparin in modulating 
proteins of coagulation cascade, heparin has been used as an anticoagulant since 1935 
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for renal dialysis and cardiac surgery. Currently heparin is obtained from porcine 
mucosa. Owing to safer and effective profile of bovine heparin, it is being re-evaluated 
to be introduced in market.15 
1.2.  Structural attributes and heterogeneity of polypeptide based drugs 
1.2.1. Sequence variants 
Sequence variants of polypeptide based drugs (protein and peptide therapeutics) 
refer to unintentional addition or substitution of amino acids during bio-manufacturing 
step. This heterogeneity at the primary structure level could be due to DNA mutations, 
misincorporation of amino acids during translation step, and mis-cleavage during post-
translational processing.16, 17 It is important to analyze the presence of sequence 
variants as it can have an overall effect on specificity, stability, and immunogenicity of 
polypeptide drugs.18 In case the amino acid occurs in the functional domain, any 
variation of this amino acid can also have an impact on the functional activity. 
1.2.2. Enzymatic and non-enzymatic post translational modifications 
Post translational modifications (PTMs) add to heterogeneity of primary 
structure by enzyme mediated covalent attachment of chemical groups to specific 
amino acids (the so-called enzymatic PTMs). Around 300 of these PTMs have been 
discovered, some which include phosphorylation, glycosylation, acetylation, 
methylation, and ubiquitination. These PTMs play an important role in modulating 
localization, stability, and interaction of proteins. For example it is known that 
phosphorylation of proteins affects their role in cell cycle, growth, apoptosis and signal 
transduction pathways. From the context of protein therapeutics glycosylation; 
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attachment of carbohydrates N-linked  to asparagine or O-linked to serine/threonine 
residues have been shown and indeed used to enhance their stability.19 
PTMs (e.g., deamidation, oxidation, glycation) can also have adverse effects on 
proteins and peptides.20, 21 These types of modifications are known as non-enzymatic 
PTMs, which occur post-production as a result of storage or stress. 
1.2.3. Higher order structure 
Correct folding of the polypeptide chain into secondary (alpha helix and beta 
sheets) and tertiary structures give rise to a unique three dimensional conformation of 
proteins. This higher order structure is not only important for the functional activity, but 
also for the stability of protein therapeutics. Unfolding or partial destabilization of the 
protein conformation (due to storage, stress or non-enzymatic PTMs) can make them 
prone to aggregation, which has an adverse effect on the safety profile of protein drugs 
by eliciting immunogenic response in patients. In the case of multimeric proteins, 
quaternary structures produced by association with identical monomeric units (homo-
oligomerization) or with non-identical units (hetero-oligomerization) play a role in 
function, localization, and stability of protein in vivo by protecting it from proteolytic 
degradation.22 
1.2.4. Second-generation protein therapeutics 
The extent of heterogeneity is enhanced in the second-generation protein 
therapeutics especially for products formed by chemical conjugation of drugs (protein – 
drug conjugates) or PEG chains on proteins post expression. Although the conjugation 
procedure is optimized carefully; it is very difficult to control the occurrence of 
 
5 
structural heterogeneity (e.g., number of drug molecules attached or presence of 
isomers due to modification at chemically similar sites), and maintain higher order 
structure. These heterogeneities affect the properties of such protein therapeutics, and 
also present great difficulty in their analytical characterization. 
1.2.5. Protein-protein interactions 
Protein-protein interactions (PPI) can be classified based on various factos.23 
Homo- or hetero-oligomers if interaction occurs between identical or non-identical 
protein chains. PPI can be distinguished if the complex formed is obligate or non-
obilgate. An obligated complex is formed between two proteins that cannot exist as 
stable structures on their own in vivo, and a non-obligate complex is formed between 
independently stable proteins. PPI can also be grouped based on binding affinity into 
permanent and transient interactions. Understanding protein-protein interactions is 
crucial as they are involved with wide range of biological processes including cell-cell 
interactions, metabolic, and developmental control. It also plays a key role in drug 
development. 
Traditionally in drug development strong interactions with the equilibrium 
dissociation constant (KD) of low nM were favored (e.g., to develop drug molecules 
binding irreversibly with the target enzyme for complete inhibition). Recently, there has 
been a shift towards exploiting lower affinity interactions (the so-called transient 
protein interactions) with KD in high nM – low µM range, due to their significance in 
cellular functions24 and also for the development of targeted drug delivery systems.25 
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1.3. Structural attributes and heterogeneity of polysaccharides (heparin-based 
medicines) 
Heparin is a mixture of linear polysaccharide chains with molecular weight 
ranging from 5000 – 25000 Da. It contains repeating disaccharide units of N-acetyl D-
glucosamine and D-glucuronic acid. The heterogeneity of heparin polysaccharide chain 
is increased by the presence of a mixture of unsubstituted forms and variable non-
template driven sulfated forms (N-and O- sulfation of glucosamine and O-sulfation of 
glucuronic acid).26 This heterogeneity has made analytical characterization of this class 
of medicine very challenging.27 The structural complexity of heparin-based medicines is 
reduced in low molecular weight heparins (LMWHs), which are produced from chemical 
or enzymatic depolymerization of unfractionated heparin. These LMWHs (e.g., tinzaprin, 
dalteparin, enoxaparin) have a mean molecular weight of 5000 Da and have been 
demonstrated to have similar anticoagulant activity as heparin.28 Arixtra is a chemically 
synthesized anticoagulant containing a fixed length pentasaccharide. 
1.4.      Commonly used analytical methods to characterize structural heterogeneity 
1.4.1. Liquid chromatography methods 
Liquid chromatography (LC) is the first line of methods to characterize structural 
heterogeneity of protein therapeutics by separating protein species using different LC 
modes. The most common LC techniques for analytical characterization are reverse 





Reverse phase liquid chromatography 
Separation in reverse phase liquid chromatography (RPLC) occurs due to 
interaction of analytes with bonded ligands of the stationary phase.29 Analytes are 
eluted in the increasing order of their hydrophobicity using organic solvent gradient. 
This type of chromatography provides excellent resolution and reproducibility, and is 
the most common technique used in combination with mass spectrometry detection 
due to ease of evaporation of the volatile solvent used for elution. RPLC/MS is an 
excellent choice for characterization of peptides; however for proteins its use is limited 
to intact mass analysis and to analyze reduced fragments of antibody. Due to the nature 
of eluent it cannot be used to analyze intact higher order structure of proteins. 
Size exclusion chromatography 
Size exclusion chromatography (SEC) is the most common technique used in 
biotechnology industry to analyze the presence of higher molecular weight species or 
aggregates in protein therapeutics. SEC separates proteins based on their hydrodynamic 
radius as they diffuse through porous particles of the stationary phase.30 Isocratic 
elution conditions (ionic strength: 100 - 150 mM) using physiological buffers in SEC 
separation maintains higher order structure of proteins, which allows it to analyze non-
covalent protein interactions. Though SEC is advantageous due to its simplicity and ease 
of use, certain limitations do exist such as non-ideality of separation due to interaction 
with stationary phase and inaccuracy of molecular weight determination from 




Ion exchange chromatography 
Ion exchange chromatography (IXC) is another separation technique in which 
protein is in its intact state due to non-denaturing conditions employed for separation. 
IXC works by electrostatic interaction of charged groups on the proteins with the ionic 
groups of the IXC resin. The pH of the eluent is decided based on the isoelectric point 
(pI) of protein being analyzed and mode of ion exchange chromatography: for cation 
exchange chromatography pH of eluent is lower than pI such that acidic groups of cation 
exchange resin can interact with net positively charged proteins and vice versa for anion 
exchange chromatography.31 Elution is carried out using linear salt or pH gradient. Ion 
exchange chromatography is extremely powerful for characterization of charge 
heterogeneity of proteins.  
1.4.2. Mass spectrometry  
Since the advent of soft ionization techniques, electrospray ionization (ESI) and 
matrix assisted laser desorption ionization (MALDI), mass spectrometry based 
techniques have developed at a very fast pace compared to any other analytical 
technique. Mass spectrometry has now become a powerful and robust tool for 
characterization of various aspects of proteins including intact mass, amino acid 
sequencing, PTM profiling, non-covalent complexes, aggregation propensity, and 
conformational integrity.32, 33 
In a typical ESI MS experiments proteins are buffer exchanged into a solution 
containing 1:1 mixture of water and organic solvent. Under these conditions proteins 
are unfolded and the multiply charged gas phase ions generated by ESI can be used to 
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measure mass accurately. High throughput hyphenated techniques (RPLC/MS or 
RPLC/MS/MS) are now being routinely used for detection of intact mass and peptide 
sequencing. Intact mass analysis with high accuracy allows identification of proteins and 
the presence of any modification. Peptide sequencing of proteins is carried out by using 
either bottom-up or top-down approach. In classical bottom-up method protein is 
digested using a protease, and the proteolytic peptides generated are analyzed by 
LC/MS or tandem MS/MS. In top-down method protein digestion step is completely 
eliminated, and the ions for sequencing are produced by fragmenting the intact multiply 
charged protein ions in gas phase. Both of these techniques (bottom-up and top-down 
MS) have been successfully applied for sequencing, localization and quantitation of 
PTMs in protein therapeutics. 
Native electrospray mass spectrometry (ESI MS) 
Unlike classical scheme native ESI MS can analyze native-like quaternary protein 
structure and non-covalent protein/receptor complexes by using near native solvents 
such as ammonium acetate.34 It has been an emerging technique and has been recently 
shown to characterize protein assemblies extending to sub-million daltons.35 
In addition to profiling mass, native ESI MS can also be used to probe large-scale 
conformational changes in protein by monitoring ionic charge state distribution in mass 
spectrum. Native proteins are compactly folded and therefore gas phase ions generated 
by ESI carry relatively fewer charges and show a narrow ionic distribution at high m/z 
region. However, unlike folded species ions generated from unfolded protein carry a 
larger number of charges and populate at lower m/z region with a broad ionic charge 
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state distribution.36 A bimodal ionic distribution will be detected under conditions when 
both compact state (highly structured native-like) and non-native states are present in 
equilibrium. 
Hydrogen deuterium exchange mass spectrometry 
Hydrogen deuterium exchange mass spectrometry (HDX) is a labelling technique 
for characterization of structure, dynamics, and the presence of multiple protein 
conformers in solution. This technique works by monitoring the exchange of backbone 
amide hydrogen with deuterium when exposed to deuterated water (D2O).37 Amide 
hydrogens of unstructured regions will show a rapid exchange compared to structured 
region, which are protected from HDX resulting in slow exchange. Mass shifts from this 
deuterium labelling can be easily measured using MS-based peptide mapping. HDX 
experiments have been used for mapping epitopes in antigen-antibody interactions,38 to 
map protein-receptor interactions,32, 39 and to compare batch-to-batch variation in 
protein therapeutics.40 
1.4.3. Light scattering based methods  
Dynamic light scattering (DLS)41 and multiangle laser light scattering (MALLS)42 
are the two light scattering techniques used for detection of higher molecular weight 
species/aggregates in protein therapeutics. Hydrodynamic radius is obtained from DLS, 
which is directly correlated with the measured diffusion coefficient.  
MALLS determines weight-average molecular weight (Mw) and radius of gyration 
(Rg) of proteins from the angular dependence of scattered light. This technique is used 
over static light scattering, when Rg is larger than angle of incident light. A typical MALLS 
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instrument consists of multiple detectors placed around the flow cell at different angles 
with respect to incident beam. Rayleigh ratio (Rθ) measured from the scattered light 
intensity at different scattering angles (θ) can be used to extrapolate Mw and Rg using 
Zimm’s equation. MALLS is usually used in combination with SEC separation, and can 
detect protein aggregates even at very low concentration.43 
1.4.4. Circular dichroism 
Circular dichroism (CD) spectroscopy of proteins is based on differential 
absorption of left- and right- polarized light in 190 – 350 nm range, which is based on 
structural asymmetry. CD measurements in far UV region 190 – 250 nm are used for 
analysis of secondary structure of proteins, and measurements in near UV region 250 – 
300 nm gives information about arrangement of the aromatic side chains and/or 
disulfide bridges within the protein. CD experiments are simple to perform, but give low 
resolution information.44 
1.4.5. Field flow fractionation 
Field flow fractionation (FFF) is a separation based technology with application in 
characterization of protein aggregates (0.01 - 50µm in size). In this method an external 
field applied perpendicular to the channel flow control retention of analytes, and 
separation occurs based on diffusion coefficients.45 Smaller molecules elute earlier than 
larger molecules. This technique is advantageous as analysis can be carried out directly 
in the formulation buffer, but the complexity of instrumentation and data handling have 
limited the widespread use of this technique. 
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1.5. Commonly used methods to analyze protein interactions 
1.5.1. Isothermal titration calorimetry 
Isothermal titration calorimetry (ITC) is a label free, solution based method to 
get equilibrium dissociation constant (KD), stoichiometry, enthalpy, entropy, and Gibbs 
free energy of protein interactions.46 It is based on measurement of heat evolved or 
absorbed upon complex formation, when ligand is titrated gradually. Slope and 
inflection point of the binding isotherm obtained from ITC can be used to derive KD and 
stoichiometry. Even though interactions with KD values of 10-9 to 10-6 M can usually be 
analyzed using ITC experiments, concentration of the protein concentration used in 
titration needs to be optimized to get the sigmoidal curve. For low affinity interactions 
high concentration of proteins needed for ITC can lead to aggregation. Another 
limitation of ITC is that it not a high throughput technique. 
1.5.2. Surface plasmon resonance 
Surface plasmon resonance (SPR) is a widely used technique for qualitative and 
quantitative characterization of protein interactions.47 In this technique one of the 
binding partners is immobilized on the sensor and the binding information is obtained 
by changes in the refractive index of the solvent near the sensor surface upon 
association or dissociation of protein complexes. SPR is advantageous as it requires 
lesser amount of proteins than ITC to measure interactions in the similar KD range. 




1.5.3. Analytical ultra centrifugation 
Analytical ultra centrifugation (AUC) is a powerful technique to characterize 
protein solution structure and to determine binding constants of protein association.48 It 
is based on real-time measurement of sedimentation of protein under centrifugal force 
along the radial position using either absorbance or interference optical systems. AUC 
experiments are operated either in sedimentation velocity (higher centrifugal field and 
completes in 1-2 hours) or sedimentation equilibrium mode (lower centrifugal field and 
takes 12 – 24 hours to complete). It can be used to derive molecular weight, oligomeric 
state, presence of aggregates, and equilibrium dissociation constant for protein 
association. Equilibrium dissociation constants in the range of 10-4 – 10-8 M can be 
detected using AUC; however aggregation of sample at higher concentration and loss of 
sample from sticking to sample chamber has to be carefully monitored. AUC data 
analysis for single species is straight forward, but complex data handling tools are 
required to analyze multi component species.45 
1.5.4. Hummel-Dreyer method 
Hummel Dreyer method is commonly used to study protein/small ligand binding, 
but can also be used for protein/protein interactions. In this method protein is dissolved 
in the buffer solution containing the same concentration of ligand used for equilibrating 
the SEC column. If there is binding between the protein and ligand a trough will be 
detected, and using the area of this trough unbound ligand concentration can be 
obtained to get equilibrium binding constant.49 The limitations of this method include 
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requirement of large amount of sample, inability to obtain kinetic data, and non-
applicability to study systems with slower binding kinetics.50 
1.5.5. Frontal analysis continuous capillary electrophoresis 
Capillary electrophoresis can be used to characterize binding of weak affinity (KD 
above 10-6 M) as long as protein/ligand complex has different electrophoretic mobility 
compared to unbound protein. Frontal analysis continuous capillary electrophoresis 
(FACCE) involves continuous sampling and electrophoretic separation. The 
electropherogram obtained from FAACE analysis shows multiple plateaus depending on 
the components in the system, and the height of the first plateau is used to determine 
the concentration of free protein to plot binding isotherms. FAACE have been applied to 
deduce stoichiometry and binding constants of protein/polyelectrolyte interactions.50, 51 
1.5.6. Affinity chromatography 
Two methods based on affinity chromatography exist for qualitative analysis of 
protein interactions.  The first method involved use of affinity purification and mass 
spectrometry for mapping protein interactions. This method involves tagging of a 
protein followed by affinity purification of tagged-proteins and identification of the 
eluted complexes using LC/MS/MS. This scheme failed to detect transient protein 
complexes unless additional crosslinking is utilized.52 
The second affinity chromatography based method was able to detect transient 
protein complex. In this elution profiles were used to confirm binding (transient binding 
of protein to the immobilized binding partner resulted in asymmetric elution profile). 
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This technique was able to detect transfer of retinoic acid to retinoic acid receptor as it 
formed a transient complex with immobilized holo CRABP II.53 
1.5.7. Fluorescence based methods 
The two most common fluorescence based techniques to quantitate protein 
interactions in vivo include fluorescence resonance energy transfer (FRET) and 
bimolecular fluorescence complementation. FRET is a non-radiative energy transfer 
between an excited fluorophore (donor) and another fluorophore (acceptor), which 
have overlapping emission/absorption spectra.54 For interacting proteins FRET occurs 
when one protein labelled with an acceptor chromophore is in close proximity (10-80 Å) 
with other protein labelled with donor chromophore. Bimolecular fluorescence 
complementation is based on association of complementary protein fragments fused to 
interacting domains of two proteins and give out a measurable fluorescence signal.55 A 
major limitation of both of these techniques is it requires attachment of reporter 
molecule to proteins, which could affect the structure of protein leading to inaccurate 
binding data. 
1.6. Objectives 
Biotherapeutics containing biopolymers have emerged to be very successful for 
the treatment of chronic diseases. However, the increased heterogeneity of 
biotherapeutics compared to small molecule drugs requires powerful and robust 
analytical tools to characterize biotherapeutics at various levels. This work reports 
multiple novel analytical methods that utilize synergy of non-denaturing 
chromatography separation (IXC, SEC) and native ESI MS detection to characterize 
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biopolymer structure and interactions. Specifically the objectives include: (i) develop 
SEC with online native ESI MS detection to characterize higher order structure of 
proteins (oligomeric states and aggregates), and probe conformational integrity 
(chapter 2); (ii) develop a label free method to measure kinetics and binding affinity of 
transient protein interactions using SEC/native ESI MS (chapter 3); (iii) develop IXC with 
online native ESI MS detection to characterize conformational integrity and positional 
isomers of protein conjugates, and glycoforms of a biotherapeutic. Implement top-down 
MS/MS in this online scheme for modifications wherein MS1 analysis could not provide 
unequivocal confirmation (chapter 4); (iv) develop a IXC/ESI MS method to characterize 












CHARACTERIZATION OF SMALL PROTEIN AGGREGATES AND OLIGOMERS USING SIZE 
EXCLUSION CHROMATOGRAPHY WITH ONLINE DETECTION BY NATIVE ELECTROSPRAY 
IONIZATION MASS SPECTROMETRY 
Peer-reviewed article published: Muneeruddin, K.; Thomas, J. J.; Salinas, P. A.; Kaltashov, I.A.; 
Characterization of Small Protein Aggregates and Oligomers Using Size Exclusion 
Chromatography with Online Detection by Native Electrospray Ionization Mass Spectrometry 
Analytical Chemistry, 2014, 86, 10692 - 10699 
2.1. Overview 
Protein self-association is a key process in a variety of diverse phenomena 
ranging from the highly ordered assembly of multiunit proteins into their functional 
states to mostly chaotic aggregation. The latter gained considerable notoriety in the 
past several decades due to its obvious role in the etiology of the so-called 
conformational diseases, such as Alzheimer’s and Parkinson’s.56-58 Renewed interest in 
protein aggregation in the biotechnology area is caused by the advent of protein 
therapeutics, where aggregation affects not only the economy of the production 
process but is also a cause of grave concerns vis-à-vis safety of biopharmaceutical 
products.59, 60 The attention in this field has been traditionally focused on relatively large 
subvisible aggregates, while small soluble oligomers were typically considered as 
transient precursors to catastrophic aggregation. However, recent studies point out that 
even reversible formation of very small oligomers (such as noncovalent dimers of 
monoclonal antibodies) may have very negative consequences by interfering with the 
drug delivery, which is triggered by increased formulation viscosity.61 The importance of 
protein aggregation places a premium on developing robust analytical methods capable 
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of detecting and characterizing protein oligomers across the entire aggregation 
spectrum. Size exclusion chromatography (SEC) and, to a lesser extent, analytical 
ultracentrifugation (AUC) are the most popular analytical tools capable of detecting 
lower molecular weight oligomers, although their utility is often limited by inadequate 
resolution.62 Light scattering42, 43, 63 and, more recently, small-angle X-ray scattering 
(SAXS)64 are also enjoying popularity in this field, although data interpretation is 
frequently model-sensitive, which limits their applicability to complex heterogeneous 
systems. 
Native electrospray ionization mass spectrometry (ESI MS) is another technique 
that enjoyed rapid growth of popularity in the studies of protein associations in the past 
two decades,34, 65, 66 with several recent examples highlighting its utility for the analysis 
of small molecular weight aggregates of therapeutic proteins. In addition to providing 
information on the stoichiometry of noncovalent protein complexes in solution, native 
ESI MS allows the structural heterogeneity of protein therapeutics to be evaluated (by 
analyzing mass profiles) and conformational integrity to be assessed (by analyzing ionic 
charge state distributions).32 However, using native ESI MS to detect and especially 
quantify noncovalent associations is not always straightforward, as artifacts are known 
to be frequently produced during the ESI process, e.g., due to forced protein self-
association during the final stages of charged droplets life when solvent evaporation 
may result in a dramatic increase of the protein concentration.67 Other factors (e.g., 
nonlinear dependence of the response factors on solution composition) may also 
complicate the quantitation efforts.68 Finally, presence of multiple oligomers in solution 
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usually results in crowded mass spectra, where overlapping peaks representing different 
oligomers can complicate the data interpretation and make it nearly impossible to 
distinguish contributions from different species. 
The ESI MS analysis of protein oligomers can be aided by SEC separation of small 
aggregates based on their physical size. Such analyses can be carried out off-line by 
collecting SEC fractions prior to their analysis,69, 70 but the results of such measurements 
can be compromised due to the possibility of the composition changes of collected 
fractions prior to MS analyses. For example, Heck and co-workers demonstrated that 
the transient nature of the small aggregates of monoclonal antibodies may result in 
their dissociation following fractionation by SEC;69 the opposite process where 
additional protein oligomerization in collected fractions is triggered by desalting and 
preconcentration is also possible.71 These problems can be circumvented by using online 
MS detection for ESI MS, but because native ESI MS is typically less sensitive compared 
to conventional ESI MS, acquisition of meaningful data on the chromatographic time 
scale remained problematic until recently. As a result, the online SEC/ESI MS detection 
scheme was only used for measuring the mass distribution of heterogeneous single-
chain macromolecules, such as synthetic polymers,72, 73 antibodies74 and antibody-drug 
conjugates,75 while the unique ability of native ESI MS to detect noncovalent biopolymer 
complexes (such as an antibody–antigen complex) has not been utilized in such 
analyses. However, the continuous improvement in ESI MS hardware has made it 
possible to carry out measurements under near-native conditions using only minute 
quantities of the analyte and relatively short acquisition time windows. We are taking 
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advantage of these expanded capabilities of native ESI MS to use it as an online 
detection tool for the analysis of noncovalent protein complexes (including both small 
soluble aggregates and highly organized self-assemblies). This combination of two 
powerful analytical techniques not only allows complex and heterogeneous protein 
mixtures to be profiled vis-à-vis the presence of protein oligomers (based on both 
retention time and mass information), but also enables assessment of protein 
conformational integrity (based on ionic charge state distributions in ESI mass spectra). 
Online detection with native ESI MS also allows meaningful information to be extracted 
from SEC chromatograms for protein assemblies that undergo rapid 
dissociation/reassociation on the chromatographic time scale. 
2.2. Materials and Methods 
Bovine serum albumin (BSA) and human transferrin (Tf) were purchased from 
Calbiochem (La Jolla, CA) and Sigma-Aldrich Chemical Co. (St. Louis, MO), respectively. A 
recombinant form of human arylsulfatase A (rhASA) was provided by Shire (Lexington, 
MA). All other chemicals used in this work were of analytical grade or higher. BSA and Tf 
solutions for online SEC/MS analysis were prepared by dissolving the protein powder 
directly in 100 mM ammonium acetate without any desalting step. Analysis of rhASA 
was carried out by diluting the drug substance sample in 100 mM ammonium acetate to 
a required concentration (0.29 to 2.3 mg/mL), and pH adjusted to a desired level using 
formic acid. 
SEC separations were carried out using Agilent 1100 HPLC (Agilent Technologies, 
Santa Clara, CA) equipped with a Waters (Milford, MA) Biosuite Ultra high resolution 
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column (4.6 × 300 mm). Typically, 100 μL of a 1 mg/mL protein solution was injected 
unless stated otherwise, and a 100 mM ammonium acetate solution (pH adjusted to a 
desired level using either formic acid or ammonium hydroxide) was used as the mobile 
phase in all separations at a flow rate of 0.1 mL/min. Upon exiting the column, the 
eluate was directed to a UV absorption detector (operated at 280 nm) followed by 
QStar-XL (ABI-Sciex, Toronto, Canada) hybrid quadrupole/time-of-flight mass 
spectrometer equipped with a standard ESI source. The ESI source conditions were 
optimized to provide a stable spray and optimal ion desolvation: drying gas, 30 L/min; 
nebulizing gas, 39 L/min; curtain gas, 22 L/min; declustering potential on the skimmer, 
290 V; declustering potential on the orifice, 160 V. The source temperature was 
maintained in the 200–250 °C interval. Collisional cooling in the ion guide region (a gas 
flow restricting sleeve in Q0) was used to enhance focusing and stability of noncovalent 
complexes. 
2.3. Results and Discussion 
2.3.1. Conformational stability and aggregation propensity of a commercial protein  
The ESI mass spectrum of bovine serum albumin (BSA) acquired under near-
native conditions (Figure 2.1) features a convoluted charge state distribution for ions 
whose masses are consistent with BSA monomer (instead of a single mass, a distribution 
of masses is observed, consistent with extensive nonenzymatic post-translational 
modifications of the protein). A bimodal character of the charge state distribution of the 
monomeric ions clearly suggests that conformational integrity of BSA is compromised: 
either a fraction of the protein molecules is partially unfolded, or all BSA molecules 
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undergo transient partial unfolding (native ESI MS alone cannot distinguish between 
these two possibilities). The presence of partially unfolded protein molecules in the BSA 
sample is not surprising, given the extent of nonenzymatic post-translational 
modification of this protein (see the convoluted shapes of peaks of BSA ions in the mass 
spectrum acquired under denaturing conditions, inset in Figure 2.1), which are known to 
change the physical properties of proteins effecting the energy barrier between folded 
and unfolded states (a detailed analysis of various forms of BSA from the commercial 
sample reveals the occurrence of several nonenzymatic post-translational modifications, 
such as cysteinylation, glycation, formation of pyridoxyl phosphate adducts, and several 
others, as shown in Figure S1 in the Supporting Information). Furthermore, production 
of commercial BSA was likely to include a thermal serum pretreatment process, which is 
usually carried out to remove any bacterial or viral contamination in the sample. 
Alternatively, the presence of partially unfolded BSA molecules in the native ESI 
mass spectrum can be explained by invoking the notion of gas phase dissociation of 
larger oligomeric ions. Should dissociation of metastable protein aggregates occur in the 
gas phase, asymmetric charge partitioning is likely to generate highly charged 
monomeric ions, a phenomenon reported in the past for other aggregation-prone 
proteins. Ionic peaks corresponding to protein dimers and higher oligomers are indeed 
observed in the higher m/z range (above 5000 u) of the BSA mass spectrum, and they 
are also present at lower m/z range (below 3500 u). It is not clear, however, if these 
ionic species represent dimers and higher oligomers existing in the protein solution at 
equilibrium with monomers, or if their presence in the mass spectrum is an artifact 
 
23 
related to forced association of proteins in rapidly shrinking electrosprayed droplets 
documented by Klassen and co-workers. The size exclusion chromatogram of BSA (gray 
trace in Figure 2.2) contains three peaks whose retention times are consistent with 
monomeric (31.5 min), dimeric (27.6 min) and trimeric (25.7 min) forms of BSA, 
although the earlier-eluting peaks could also be interpreted as partially unfolded protein 
monomers. Therefore, neither native ESI MS nor SEC alone can provide unequivocal 
characterization of the protein sample which is prone to both partial unfolding and 
oligomerization. 
The uncertainties regarding the data interpretation are readily resolved by 
combining SEC separation with online native ESI MS detection. The appearance of the 
total ion chromatogram (TIC) is consistent with the shape of the UV trace in that three 
partially resolved peaks can be identified (Figure 2.2); however, the ability of MS to 
identify ionic species giving rise to each TIC peak allows this chromatogram to be readily 
interpreted. For example, only trimeric protein species are present in the earliest eluting 
peak, allowing it to be assigned as a BSA trimer. Importantly, both high- and low-charge 
density trimer ions are observed in the mass spectrum averaged across this peak (see 
inset in Figure 2.2), indicating that BSA trimers undergo reversible and rapid (on the SEC 
time scale) loss of compactness. A very similar behavior is exhibited by the protein 
dimers, where both low-charge density ions (m/z > 5000 u) and high-charge density 
ones (m/z < 3000 u) are prominent in the mass spectrum averaged across the second 
SEC peak. No BSA monomers can be observed in either of the spectra averaged across 
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the early eluting peaks, clearly indicating that the transient loss of higher order structure 
within both dimers and trimers does not result in their dissociation. 
The most prominent ionic species in the mass spectrum averaged across the 
latest eluting SEC peak corresponds to BSA monomers. The charge state distribution is 
bimodal, indicating presence of both compact and partially unfolded proteins. 
Importantly, the extracted ion chromatograms for both high- and low-charge density 
monomeric ions exhibit virtually indistinguishable elution profiles (right inset in Figure 
2.2), which unequivocally demonstrates that the two forms of the protein are in rapid 
equilibrium with each other, and their separation cannot be achieved by SEC alone. In 
addition to the BSA monomers, the mass spectrum averaged across the latest eluting 
peak contains contributions from oligomers. Because the extracted ion chromatogram 
for these ions closely follows that of the monomeric ions in the 30–35 min time window, 
these oligomers represent nonspecific association of proteins in rapidly shrinking 
electrosprayed droplets in the ESI interface, a well-known artifact of ESI MS.76 Thus, SEC 
with online native ESI MS detection not only provides a convenient way for detecting 
and characterizing all protein species present in solution but also allows the ESI MS 
artifact to be readily identified and eliminated from the analysis. 
A very intriguing question that arises in connection with the analysis of BSA 
oligomers is the nature of the protein/protein association that leads to their formation. 
Although it is frequently assumed that these species are formed through noncovalent 
interactions, the possibility of covalent interactions being involved in the early stages of 
BSA aggregation cannot be excluded. Indeed, BSA has one free cysteine residue, which 
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might participate in formation of external disulfide bonds (unless protected by 
cysteinylation, as seen in at least some BSA molecules, see Figure S1 in the Supporting 
Information). One can also argue that formation of higher oligomers may proceed 
through disulfide scrambling leading to formation of multiple external disulfide bonds. 
However, the ESI mass spectrum of BSA acquired under denaturing conditions does not 
contain signals corresponding to protein dimers and tetramers, indicating the reversible 
nature of the association process. Furthermore, dissociation under nonreducing 
conditions is also evident in SEC chromatograms of oligomeric fractions of BSA (see 
Figure S2 in the Supporting Information). 
It is interesting to note that albumin in fresh human plasma does not exhibit 
many features that are prominent in the mass spectra of commercial BSA. For example, 
we note that the high-charge density peaks are absent from the ESI mass spectrum 
acquired under near-native conditions, and the protein mass profile does not exhibit the 
same high level of heterogeneity as BSA (see Figure 2.3). The two major forms 
correspond to intact protein and cysteinylated protein,77 with all other forms being 
relatively minor contributors. The mass difference between these two forms of albumin 
is sufficient enough to allow extracted ion chromatograms for each of them to be 
plotted separately, without the interference from the other form. The overlaid plots of 
the two extracted ion chromatograms (for intact and cysteinylated human serum 
albumin) display identical elution profiles, indicating that cysteinylation of the only free 
cysteine residue in albumin does not compromise its conformational integrity (Figure 
2.3). Unfortunately, the multiplicity of nonenzymatic PTMs observed in the commercial 
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BSA sample does not allow adequate resolution to be achieved under the native 
conditions to afford selective monitoring of these species in SEC/MS. 
We note that the online analysis of BSA aggregates carried out in this work using 
native ESI MS as a detection tool can also be accomplished using other tools, such as 
multiangle light scattering (MALLS).63 However, as can be seen from the following 
sections, SEC with online detection by native ESI MS has a unique advantage of being 
able to provide meaningful information when analyzing coeluting proteins of different 
masses, a task that remains very challenging for MALLS. One potential concern related 
to the analysis of protein aggregates by SEC/MS is the use of volatile electrolytes (such 
as ammonium acetate) as solvent systems. Although long-term exposure of proteins to 
ammonium acetate or similar solvent systems may have the potential to affect their 
aggregation propensity, the short time required for a single SEC/MS experiment makes 
such changes unlikely. Indeed, comparison of aggregation profiles extracted from SEC 
chromatograms acquired with ammonium acetate and a conventional phosphate buffer 
as mobile phases revealed no differences outside of the experimental error (see Figure 
S3 in the Supporting Information). The distribution of protein aggregates also appears to 
be insensitive to the SEC flow rate (see Figure S4 in the Supporting Information), giving 
indication that the measurements are unlikely to be affected by the shear flow around 
the stationary phase particles.  
2.3.2. Analysis of coeluting proteins  
Analysis of protein mixtures where the difference in molecular weight (or, more 
correctly, hydrodynamic radii) does not allow adequate chromatographic resolution to 
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be achieved is a frequently encountered problem in SEC. The ability of online SEC/native 
ESI MS to provide meaningful information for such systems was illustrated by analyzing 
the equimolar mixture of BSA and human serum transferrin (Tf). The molecular weights 
of these two proteins (66 and 80 kDa, respectively) are too close to each other to allow 
satisfactory separation to be achieved using SEC. Indeed, the SEC chromatogram (UV 
trace) shows a large peak with a convoluted shape consistent with the presence of two 
abundant proteins having very close elution times (Figure 2.4, left panel). Although the 
SEC alone fails to provide a clear distinction between BSA and Tf, online detection with 
native ESI MS allows the elution profiles of both proteins to be determined (see the 
extracted ion chromatograms for the +16 charge state of Tf and the +14 charge state of 
BSA in Figure 2.4). The data presented in Figure 2.4 are also notable for another reason: 
unlike BSA, ionic charge state distribution of Tf does not exhibit bimodal character, with 
only low-charge density ion peaks present in the mass spectra (e.g., see the lower trace 
in the right panel of Figure 2.4). This suggests that partially unfolded Tf molecules are 
not present in the sample; incidentally, the SEC/MS data also fails to reveal the presence 
of oligomeric forms of Tf (only BSA dimers and trimers could be observed, as shown in 
Figure 2.4, right panel). 
Another important observation from the analysis of extracted ion 
chromatograms of BSA and Tf is that the elution order is not the same as the molecular 
weight order (Tf is larger). Furthermore, Tf has a bilobal structure,78 whereas albumin 
has a globular fold,79 which should make the difference in hydrodynamic radii even 
larger. Nevertheless, the extracted ion chromatograms for BSA and Tf monomers clearly 
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show shorter elution time for the former. Although it is possible that the longer 
retention time of Tf molecules may be related to their interactions with the column 
packing material beyond purely mechanical interactions (filtration), a more likely cause 
for this anomalous behavior is the increase of the average hydrodynamic radius of BSA 
monomers due to their transient unfolding during the separation process. 
2.3.3. Characterization of protein self-association: arylsulfatase A  
Both proteins considered in the previous sections (BSA and Tf) are monomeric, 
and formation of oligomeric species is a clear sign of degradation. However, ordered 
noncovalent association of several polypeptide chains is frequently required in order to 
endow proteins with specific properties. Formation of the requisite quaternary structure 
is frequently reversible, as is the case with arylsulfatase A, a critical lysosomal enzyme 
that exits as a homodimer at neutral pH, but must assemble into octamers at mildly 
acidic pH to avoid degradation by lysosomal proteases.22, 80 Recently, we demonstrated 
that SEC correctly identifies homodimeric and homo-octameric arrangements as 
quaternary structures of the recombinant form of human aryl sulfatase A (rhASA) at pH 
7.0 and 5.0, respectively.81 However, SEC analysis of rhASA at intermediate pH (between 
6.1 and 6.9) failed to provide conclusive results, yielding only broad unresolved peaks 
whose profiles were both pH- and concentration-dependent, and the average elution 
time did not match that of either dimers or octamers. At the same time, native ESI MS 
analysis carried out within this intermediate pH region revealed the presence of only 
dimeric and octameric species of rhASA,81 suggesting that the two forms of the protein 
coexist at a dynamic equilibrium, and their interconversion (dissociation/reassociation) 
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is very fast on the chromatographic scale, which does not allow these species to be 
distinguished from one another by SEC. 
Online SEC/ESI MS analysis of rhASA at the two terminal pH points (5.0 and 7.0) 
confirms that the protein exists as an octamer and a dimer, respectively (Figures 2.5 and 
2.6). Interestingly, the single peak in SEC chromatogram acquired at pH 7.0 (elution time 
30 min) contains contributions from both dimeric and octameric ions, although their 
elution profiles are indistinguishable (compare the extracted ion chromatograms for the 
two groups of ions in Figure 2.6). This strongly indicates that the octameric ions of 
rhASA observed at neutral pH do not reflect protein association in solution, but rather 
represent the artifacts related to the forced association in the ESI interface, similar to 
what had been observed for BSA (vide supra). 
SEC/ESI MS analysis of rhASA carried out at intermediate pH 6.4 yields a total ion 
chromatogram that also contains contributions from both octameric and dimeric ions 
(Figure 2.7), although their respective extracted ion chromatograms differ from each 
other in a very dramatic way. The elution profile of the octameric protein species is very 
close to that recorded under the mildly acidic conditions (Figure 2.5). In contrast, the 
elution profile of the dimers has a convoluted form with the elution front coinciding 
with that of the octameric species, and tailing all the way to the elution window 
observed for rhASA dimers at neutral pH (Figure 2.6). This significant dissimilarity of the 
elution profiles of rhASA dimers and octamers observed at intermediate pH indicates 
that the octameric species dissociate as they move through the column. Indeed, if we 
denote the linear velocity of stable octamers and dimers as u8 and u2 (u8 > u2), which 
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relate to the column length L and the observed elution times T8 and T2 (e.g., those seen 
in Figures 2.5 and 2.6) as uk = L/Tk, then the elution time of the dimer t2 produced upon 
dissociation of the octamer at time τdiss (τdiss < T8) can be calculated as 
𝑡2 = 𝜏𝑑𝑑𝑑𝑑 +
𝐿−𝜏diss∙𝑢8
𝑢2
= 𝑇2 − 𝜏𝑑𝑑𝑑𝑑 ∙ �
𝑇2
𝑇8
− 1�                                                            (1)                                                                    
In other words, the elution times of the dimers formed on the column will spread 
between T8 and T2. The shape of this distribution can be used to determine the kinetics 
of the octamer dissociation (e.g., to establish the distribution of τdiss), although no such 
calculations were performed in this work due to insufficient chromatographic 
resolution. 
Dissociation processes alone do not account for all of the chromatographic features 
observed in Figure 2.7: even though the extracted ion chromatogram of the octameric 
species has a sharp frontal edge (similar top that seen in Figure 2.5), there is a small (but 
measurable) delay in the elution. Furthermore, the shape of this chromatogram is 
asymmetric, as a slight tailing toward longer elution times is observed (a feature that 
was absent in the octamer elution profile in Figure 2.5). These two phenomena cannot 
be explained without invoking the notion of reassociation of the products of dissociation 
(dimers generated during the chromatographic run) to yield octamers. A simplified 
mathematical treatment of the reassociation process can be carried out by assuming 
that a new octamer is formed via association of four dimers, all of which were produced 
at a single time point τdiss (i.e., by ignoring the possibility of multiple 
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dissociation/reassociation events throughout a single chromatographic run). In this 
case, the elution time of the newly formed octamer can be estimated as 
𝑡8∗ = 𝜏𝑑𝑑𝑑𝑑 + 𝜏𝑟𝑟𝑟𝑑𝑑 +
𝐿−𝜏diss∙𝑢8−𝜏reass∙𝑢2
𝑢8
= 𝑇8 − 𝜏𝑟𝑟𝑟𝑑𝑑 ∙ �1 −
𝑇8
𝑇2
�                                          (2) 
where τreass is the time interval between formation of the dimers and their reassociation 
back to an octamer. Of course, a more rigorous mathematical treatment should take 
into account the possibility of multiple dissociation/reassociation events, which would 
require numerical simulations. Nevertheless, the simple algebraic expression 2 is useful 
and informative as a way to rationalize the tailing of the elution profile of rhASA 
octamer in Figure 2.7, and might be used to obtain a first-order approximation of the 
distribution of τreass, especially under conditions when the extent of the dissociation 
during the chromatographic run is limited. 
Because the kinetics of the reassociation process should be concentration dependent, 
one would expect to observe a shift in the elution front of the octameric species 
following the decrease of protein concentration. Decrease in rhASA concentration from 
2.3 to 1.1, 0.55 and 0.29 mg/mL (while keeping the acidity constant at pH 6.4) resulted 
in a progressive decrease of the relative abundance of the octameric species and also 
led to a noticeable change of their elution profiles (shift of the elution front to longer 
times and enhanced peak tailing, see Figure 2.8), consistent with the expected 
equilibrium shift toward the dissociation products when the overall protein 
concentration goes down. A similar trend was observed under more acidic conditions 
(pH 6.1), where total protein concentration reduction from 1.1 mg/mL to 0.29 mg/mL 
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resulted in a monotonic decrease of the relative ionic signal of octameric species and a 
shift of the octamer elution front (see Figure S5 in the Supporting Information). 
It is important to note that even though the partial dissociation of rhASA octamers at pH 
6.4 might be inferred from SEC alone by observing the trailing of the UV trace of SEC 
chromatograms to longer elution times (e.g., see the brown trace in Figure 2.7), it is the 
ability of MS to make a clear distinction between the dimeric and octameric ions that 
allows the underlying cause of this peak broadening to be readily established. We also 
note that the extent of peak broadening of the TIC is much more significant compared 
to the UV trace, as dissociation of an octamer to four dimers does not change the UV 
absorbance (as the total number of aromatic residues remains unchanged), while the 
ionic signal increases (as the number of molecules capable of producing ions increases 
4-fold). 
Online detection with native ESI MS also allows another interesting phenomenon to be 
observed, which relates to the uneven concentration profiles across chromatographic 
peaks and is very important vis-à-vis establishing the realistic limits for the accuracy of 
the SEC-based measurements. As has been already mentioned, kinetics of the 
reassociation process are concentration-dependent (unlike octamer dissociation, which 
is a unimolecular process). Therefore, it seems plausible that the octamer/dimer 
equilibrium will be shifted toward the latter not only at the “far end” of the 
chromatographic peak (as can be seen by comparing the elution profiles of octamers 
and dimers in Figure 2.7), but also at the “front end” of the chromatographic peak. 
Indeed, a careful analysis of the elution profiles of the two oligomeric species at the 
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elution front provides unequivocal evidence that the dissociation process is strongly 
favored during a very short time interval at the elution front (Figure 2.9). Indeed, while 
the extracted ion chromatogram of the octameric species displays a monotonic 
increase, reaches an apex and begins to decrease monotonically, the elution front of 
dimers has a very sharp edge followed by a rapid drop in intensity (with the minimum 
intensity for M2 coinciding with the apex of the M8 peak) before the “normal” behavior 
is observed. The width of the aberrant peak at the front of the elution profile of dimeric 
species defines the lower resolution limit for kinetic measurements that can be carried 
with the SEC/native ESI MS. 
2.4. Conclusions 
The SEC/native ESI MS analysis of proteins and their assemblies presented in this work 
provides an elegant way to characterize complex mixtures of proteins that include both 
monomeric species, their low molecular weight soluble aggregates and larger 
assemblies. A distinction can be readily made among the incompletely resolved proteins 
based on their mass differences, and the analysis of protein ion charge state distribution 
allows the conformational integrity to be assessed. The ability to resolve different 
protein assemblies based on their masses allows a meaningful analysis to be carried out 
when such species cannot be separated from one another by means of SEC alone due to 
their rapid interconversion on the chromatographic time scale. Importantly, the new 
technique does not require the protein samples to be purified/desalted prior to the 












Figure 2.1 ESI mass spectrum of BSA acquired under near-native conditions without SEC 
separation of protein monomers and oligomers. The mass spectrum acquired under denaturing 
conditions is shown in the inset (only 1000–2000 m/z range is shown, as no protein ions were 





Figure 2.2 Online SEC/MS analysis of BSA: UV chromatogram (gray); TIC (black); extracted ion 
chromatograms of the BSA monomers (blue, +14 charge state), dimers (magenta, a sum of +20 
and +21 charge states) and trimers (brown, a sum of +25 and +26 charge states). Inset on the 
left shows mass spectra averaged across the three SEC peaks (acquisition times are indicated 
on each trace). Inset on the right shows extracted ion chromatograms of compact and partially 














Figure 2.3 Extracted ion chromatograms for two forms of human serum albumin (intact, blue; 
cysteinylated, red) in blood plasma. The inset shows the spectrum of the protein averaged 
across the SEC peak and the zoomed view of the ion peak corresponding to +14 charge state 














Figure 2.4 Online SEC/MS characterization of an equimolar mixture of BSA and Tf: UV 
chromatogram (black); TIC (gray); extracted ion chromatograms of the BSA monomers (blue, +14 
charge state), BSA dimers (charge state +20, magenta) and Tf monomers (charge state +16, red). 
Inset shows mass spectra averaged across the three SEC peaks (acquisition times are indicated 












Figure 2.5 Online SEC/MS of rhASA (1.1 mg/mL) at pH 5.0: UV chromatogram (brown), TIC 
(black) and the cumulative extracted ion chromatogram of the octameric species (red). Inset 












Figure 2.6 Online SEC/MS of rhASA (1.1 mg/mL) at pH 7.0: UV chromatogram (brown), TIC 
(black) and the cumulative extracted ion chromatograms of the dimeric (blue) and octameric 










Figure 2.7 Online SEC/MS of rhASA (2.3 mg/mL) at pH 6.4: UV chromatogram (brown), TIC 
(black) and the cumulative extracted ion chromatograms of the dimeric (blue) and octameric 





Figure 2.8 Elution profiles of the octameric species of rhASA acquired with online SEC/ESI MS at 
pH 5.0, protein concentration 1.1 mg/mL (red trace) and pH 6.4, protein concentrations (from 



















Figure 2.9 Zoomed views of the elution profiles of octameric (red) and dimeric (blue) species of 













Figure S1. Mass profile of BSA from a commercial source deconvoluted from a mass spectrum 





Figure S2. Elution profiles of unfractionated BSA (black trace) and re-injected fractions of 
trimers (blue), dimer (red) and monomers (brown) showing dynamic character of low molecular 



















Figure S3. Size distribution of BSA low molecular weight aggregates from SEC 
chromatograms (UV detection only) acquired with ammonium acetate (left) and 
phosphate buffer (right) as mobile phases. The colored bars represent monomers (brown), 









Figure S4. Size distribution of BSA low molecular weight aggregates (top) and representative 









Figure S5. Elution profiles (extracted ion chromatograms) of the octameric species of rhASA 
acquired with on-line SEC/ESI MS at pH 5.0, protein concentration 1.1 mg/mL (red trace) and 




MEASURING KINETICS AND AFFINITY OF TRANSIENT PROTEIN-RECEPTOR 
INTERACTIONS USING SIZE EXCLUSION CHROMATOGRAPHY WITH ONLINE NATIVE ESI-
MS DETECTION 
3.1. Overview 
Protein-protein interactions play an important role in diverse areas of life science 
research including evaluation of cellular functions and also to aid in the development of 
therapeutics. Due to this there has always been a tremendous need of analytical 
methods to characterize and provide accurate information on kinetics and 
thermodynamics of protein interactions.  
Traditionally, strong interactions with the equilibrium dissociation constant (KD) 
of low nM were favored (e.g., to develop drug molecules binding irreversibly with the 
target enzyme for complete inhibition). Recently, there has been a shift towards 
exploiting lower affinity interactions (the so-called transient protein interactions) with 
KD in high nM – low µM range, due to their significance in proper functioning of living 
cells and also for the development of targeted drug delivery systems.24, 25, 82 In the case 
of drug delivery systems transient protein interactions help not only in efficient binding 
of carrier protein to extracellular receptor, but also in its release after transporting 
inside the cells. A strong binding in this case will have unfavorable consequences by 
impeding the release of drug carrier from the protein receptor. Design of efficient 
targeted drug delivery strategies also critically depends on the availability of the kinetic 
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data, as the timing of the drug dissociation from its carrier is important for successful 
delivery. 
A wide variety of analytical methods have been developed to characterize 
protein interactions, however owing to weak binding of transient protein interactions it 
is technically difficult to detect them compared to stronger interactions. Some of the 
most commonly used methods include surface plasmon resonance (SPR),83 analytical 
ultracentrifugation (AUC),84 isothermal calorimetry (ITC),85 and tandem affinity 
purification-mass spectrometry (TAP-MS).52 Majority of these methods have 
disadvantages that invariably affect the binding characteristics such as requirement of 
protein immobilization in SPR could alter structural properties of proteins, inability to 
detect transient complexes in TAP-MS without any additional crosslinking, and large 
concentration of proteins required for ITC and AUC. In vivo analysis of protein 
interactions can be carried out using fluorescence based assays (e.g., fluorescence 
resonance energy transfer (FRET) and bimolecular fluorescence complementation 
(BiFC), however these methods require labeling of proteins with fluorophores, which 
could again lead to a change in structure of protein.86 A limitation common to all of 
these techniques is their inability to deal with highly heterogeneous systems frequently 
encountered in the field of biotherapeutics. 
In the past two decades native electrospray ionization mass spectrometry (ESI 
MS) has enjoyed growing popularity to characterize structure of non-covalent protein 
assemblies.34 In chapter 2, the advantages of combining separation by size exclusion 
chromatography with native ESI MS detection to characterize aggregation, 
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conformation, and rapidly equilibrating protein oligomers were presented.87 Although 
relating ionic abundance of protein species with fractional concentration in solution is 
not straightforward due to differences in their ionization and transmission efficiencies, 
there have also been reports of using native ESI MS to quantify binding affinities.88 
In this chapter a new label-free analytical method to measure kinetics and 
binding affinity of transient protein interactions is reported. This method is based on the 
SEC/native ESI MS method developed in chapter 2. Here we have developed a 
mathematical model to explain the transfer of dynamic protein species through the 
column, and by fitting the profile generated from this mathematical solution with the 
extracted ion chromatograms (XICs) of SEC/MS binding and kinetic parameters of 
transient protein interactions can be extracted. In this chapter first an explanation for 
the elution behavior of recombinant arylsufatase A (rhASA) detected in chapter 2 is 
given and then this is extended to protein/receptor interactions to obtain kinetics and 
binding information. We have validated this method using known binding of transferrin 
variants with soluble form of transferrin receptor.89, 90 
3.2. Materials and Methods 
Holo human transferrin (hTf) and holo bovine transferrin (bTf) were purchased 
from Sigma-Aldrich Chemical Co. (St. Louis, MO). Soluble ectodomain transferrin 
receptor (TfR), C-lobe and N-lobe of transferrin were generously provided by Prof. Anne 
B. Mason (University of Vermont College of Medicine, Burlington, VT). Iron-free forms 
(Apo) of transferrin were prepared by acid-denaturing the protein in the presence of 
EDTA followed by centrifugal ultrafiltration (30k molecular-weight-cutoff vivaspin filters) 
 
51 
to 100 mM ammonium acetate. All other chemicals used in this work were of analytical 
grade or higher. Tf/TfR solutions were mixed in 2:1 molar ratio by diluting from stock 
solution, and after equilibration were analyzed by SEC/ESI MS without any desalting 
step. 
SEC separations were carried out using Agilent 1100 HPLC (Agilent Technologies, 
Santa Clara, CA) equipped with a Tosoh (Tokyo, Japan) TSKgel G3000 SWxl column (7.8 × 
300 mm) and a 100 μL injection loop. Ammonium acetate solution (100 mM, pH 7) was 
used as the mobile phase in all separations at a flow rate of 0.5 mL/min. After exiting 
the UV detector (operated at 280 nm), using a 1:1 flow splitter the flow rate of eluate 
directed to ESI MS was set at 0.25 ml/min. 
ESI MS detection was carried out using QStar-XL (ABI-Sciex, Toronto, Canada) 
hybrid quadrupole/time-of- flight mass spectrometer equipped with a standard ESI 
source. The ESI source conditions were optimized to provide a stable spray and optimal 
ion desolvation: drying gas, 30 L/min; nebulizing gas, 39 L/min; curtain gas, 22 L/min; 
declustering potential on the skimmer, 290 V; declustering potential on the orifice, 160 
V. The source temperature was maintained in the 200 − 250°C interval. Collisional 
cooling in the ion guide region (a gas flow restricting sleeve in Q0) was used to enhance 
focusing and stability of noncovalent complexes. 
3.3. Theory 
In chapter 2 SEC/ESI MS analysis of recombinant arylsulfatase A (rhASA) at pH 
6.4 yielded asymmetric peak shape for XICs of ocatmers (M8) and diffused pattern for 
dimers (M2). This observation can explained by taking into account multiple dissociation 
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events of octamers to dimers followed by re-association of newly formed dimers to 
octamers over the fixed column length (L). This behavior is illustrated in figure 3.1 using 
a 2-dimensional plot (distance traveled inside the column vs. the travel time). Taking 
into consideration these dynamic reactions along with diffusion and mass transfer of 
analytes a mathematical solution can be constructed for transfer of octamers and 
dimers through the column as shown in equation 1. This system is a one-dimensional 
version of the so-called advection-diffusion-reaction (ADR) equation,91 which is 
frequently encountered in chemical engineering, the two significant differences being 
unequal mass transfer coefficients uM8 and uM2 (the flow velocity is the same for all 



























+ 4𝑘−4𝐶𝑀8 − 2𝑘2𝐶𝑀22
                                                (1) 
(assuming a short lived intermediate tetramer (M4) during M2 ⇌ M8 transition of 
rhASA)80 
uM8, uM2: Linear velocity of octamers and dimers, respectively. 
DM8, DM2: Diffusion coefficient of octamers and dimers, respectively. 
Varying k2 and k-4 will generate a family of solutions for equation 1, from which 
the best match with the experimental data will be selected, followed by generating 
another family of solutions by varying the parameters k2 and k-4 within a narrower 
range, etc. This optimization routine will eventually produce kinetic parameters that are 
best fits for the experimentally measured XIC profiles of M8 and M2. 
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In this chapter the approach presented above to study homo-oligomerization of protein 
have been applied to protein/receptor interaction systems. 
For protein and receptor that interacts to form a 1:1 complex (equation 2). 
𝑃 · 𝑅 ⇌𝑘1
𝑘−1⇌ 𝑃 + 𝑅                                                                                                                        (2)                                                                                                                     
The interacting partners (P, R, and P·R) have different size, and therefore would 
travel with different linear velocities during trajectory inside the column. Due to this 
difference the dissociation products generated in a single dissociation event will not be 
able to re-associate (as shown in figure for a hypothetical protein receptor system).  
However, physical interaction leading to reassociation of P and R will be possible if their 
trajectories intercept as they are formed in two different dissociation events (grey 
circles in figure 3.2). The partial derivative equations describing dynamic P·R complex is 
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+ 𝑘−1𝐶𝑃𝑅 − 𝑘1𝐶𝑃𝐶𝑅
                                                           (3) 
 
  
Partial derivative equations 5 are a straight forward modification of equation 3 for 
bivalent system in which the receptor (R) can bind to two protein molecules 
𝑃2𝑅 ⇌𝑘2
𝑘−2 𝑃 + 𝑃 · 𝑅;    𝑃 · 𝑅 ⇌𝑘1














































+ 𝑘−1𝐶𝑃𝑅 − 𝑘1𝐶𝑃𝐶𝑅                                                     
            (5) 
3.4. Results and Discussion 
SEC/ESI MS analysis of non-covalent protein assemblies stable in solution on the 
chromatographic time scale give rise to well-defined peaks whose elution time is 
consistent with the hydrodynamic size (also controlling the linear velocity) of each 
species. An example is shown in figure 3.3, where incubation of the metalloprotein 
transferrin (Fe2Tf) with the soluble ectodomain of transferrin receptor (TfR) resulted in 
formation of a stable 2:1 complex, detected as an earlier eluting peak. In this case online 
detection with native ESI MS provides confirmation based on their masses (i.e., an early-
eluting 322 kDa (Fe2Tf)2·TfR complex, and a late-eluting 79 kDa Fe2Tf, which was present 
in the mixture in molar excess). A failure to form a protein/receptor complex would be 
confirmed by the absence of the early-eluting species in the chromatogram, as 
illustrated in Figure 3.3 for the mixture of TfR and Tf N-lobe (Tf loses its receptor-binding 
competence upon removal of the C-lobe).89  
3.4.1. Protein-receptor complex interacting with 1:1 stoichiometry 
A model system of 1:1 complex was made by mixing molar excess of C-lobe form 
of human transferrin (FeTfC) with transferrin receptor (TfR), which has already been 
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shown using orthogonal approaches to have a weak affinity.89, 90 As shown in figure 3.4 
the XICs obtained from the SEC/ESI MS analysis of this mixture is convoluted. The XIC 
behavior of free FeTfC and 1:1 complex (FeTfC·TfR) follows the pattern shown in figure 
3.2; FeTfC·TfR complex peak (purple trace in figure 3.4) is asymmetrical with significant 
tailing and the dissociation products that fail to re-associate appear in chromatograms 
as early eluting free FeTfC molecules (16.1 – 17.5 min interval). 
Figure 3.5 illustrates a family of solutions generated for each of the interacting 
species (blue - FeTfC, red - TfR, and purple - FeTfC·TfR complex) using equation 3. 
Symmetrical peaks shapes with elution time characteristic of their linear velocity were 
generated, when dissociation channels were turned off. Opening only the dissociation 
path for the complex (k-1 = 0.015) shows distinct features that include decrease in 
abundance FeTfC·TfR complex peak, increase in abundance and broadening of TfR peak, 
and monotonic trailing of FeTfC to early elution time interval. Opening both dissociation 
and association of complexes (k1 = 1.3.104 and k-1 = 0.020) led to tailing and shift of 
FeTfC·TfR complex to later elution time as these complexes are formed as a result of 
reassociation of interacting partners on the column, and a bimodal trailing of FeTfC was 
also seen.  
Based on these observations a family of solutions were generated to get a close 
match fit with experimental chromatograms (figure 3.6). In our optimization steps a 
solution was considered a match if its peak shape and elution time aligned with the 
experimental chromatograms. As TfR signal was not recorded, we have used 
chromatograms of FeTfC and FeTfC·TfR complex to get a match. By not taking absolute 
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abundance of each of these species into consideration, any artifacts generated due to 
differences in ionization and transmission efficiency are avoided. Following this 
optimization routine for FeTfC and TfR interaction, we detected kinetic rates of k1 = 3.3 x 
107 M-1 min-1and k-1 = 3.0 min-1. This gives an equilibrium dissociation constant of 90nM. 
3.4.2. Protein-receptor complex interacting with 2:1 stoichiometry 
Validation of this method to characterize binding of a 2:1 protein/receptor 
complex was carried out using transferrin variants. The affinity of these transferrin 
variants to human TfR has already been reported to cover a broad range using 
orthogonal approaches.89 Figure 3.7 illustrates experimental data for binding of three 
transferrin variants; apo human transferrin (hTf), holo bovine transferrin (Fe2 bTf), and 
apo bovine transferrin (bTf) interacting with TfR. These chromatograms are highly 
convoluted and differ significantly from those detected for Fe2hTf/TfR interaction (figure 
3.3). First, Tf·TfR complexes of both 2:1 and 1:1 stoichiometries are observed despite 
excess of the protein over the receptor in the injection mixture. Second, the elution 
profiles of the 2:1 complexes (Tf2·TfR) are asymmetrical and are shifted compared to the 
elution time of the (Fe2hTf)2·TfR complex (shown in Figure 3.7 with a dotted line). This is 
consistent with the notion of the vast majority of 2:1 complexes not surviving the 
chromatographic run and dissociating prior to elution from the column; the observed 
complexes are formed within the column as a result of re-association processes. The 
second, third… generation of dissociation products that fail to re-associate appear in 
chromatograms in Figure 3.7 as early eluting free Tf molecules (14.5 – 17.5 min interval) 
and 1:1 complexes. 
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Generating a family of solutions for (Tf)2·TfR, Tf·TfR, and Tf species using equation 5 and 
optimizing them by varying kinetic rate constants (k1, k-1, k2, and k-2) yielded a close 
match profile as shown in figure 3.8. Based on these kinetic rates, equilibrium 
dissociation constants were obtained for transferrin variants used in this validation 
study. As expected the equilibrium dissociation constants (KD1 and KD2) for hTf and Fe2 
bTf were in higher nano molar range, and very weak binding with KD1 in micro molar and 
KD2 in higher micro molar for interaction of bTf with human TfR was detected.  
3.5. Conclusions 
A label-free method using SEC with online ESI MS to obtain kinetic and thermodynamic 
parameters of transient protein interactions has been presented. Strong protein 
complexes that do not dissociate on the chromatographic timescale will be outside of 
reach of this method. In this study we have validated this new method for transient 
protein interactions (protein/receptor complexes) with both 1:1 and 2:1 
stoichiometries. In a similar way this method can also be extended to transient protein 
interactions with higher stoichiometries as long as each of the interacting species have 

















Figure 3.1 Schematic 2-D diagram illustrating behavior of M8 and M2 species during the SEC 
analysis of metastable rhASA octamers. Stable species would travel only along the trajectories 
on the far left (M8) and far right (M2), but the actual trajectories branch out as a result of M8 
dissociation (white circles) and M2 re-association (gray circles). Red and blue circles show 












Figure 3.2 Illustration of behavior of two interacting species (P, protein, and R, receptor) during 
the SEC run. All three species are present at the time of injection. Products of P·R dissociation 





Figure 3.3 SEC and SEC/ESI MS characterization of transferrin binding to its receptor with high 
affinity (full-length, iron-saturated human Tf, top) and failing to form a complex with the 
receptor (N-terminal half of human Tf, bottom). The three traces show UV chromatograms of Tf, 
TfR and their mixtures. Extracted ion chromatograms of the protein/receptor complex (purple) 






Figure 3.4 SEC/ESI MS characterization of C-lobe form of transferrin (FeTfC) binding to 
transferrin receptor (TfR). The three traces show UV chromatogram (grey), and extracted ion 














Figure 3.5 Family of solutions generated using initial set of rate constants as shown in 
each panel. The three traces show extracted ion chromatograms of FeTfC (blue), TfR 
(red), and FeTfC·TfR complex (purple). Filled blue and red traces (extracted ion 
chromatograms of FeTfC and TfR, respectively at k1, k-1 = 0) are overlaid in middle and 



















Figure 3.6 Extraction of rate constants for FeTfC/TfR binding and dissociating using experimental 
SEC/ESI MS data. The calculated elution profiles are overlaid to get the best match. Calculated 
profile using rate constants of k1= 3.3 x 107 M-1 min-1and k-1 = 3.0 min-1 (green) was considered 




Figure 3.7 SEC/ESI MS analysis of transient Tf/TfR complexes. Tf elution profiles are shown with 
blue curves, and elution profiles of Tf·TfR complexes are shown with orange (1:1 stoichiometry) 





Figure 3.8 Extraction of rate constants for Tf/TfR binding and dissociating using 
experimental SEC/ESI MS data. The calculated elution profiles that were good match with 
experimental data are shown. Calculated elution profile of Tf (solid black trace), Tf·TfR 
complexes with 2:1 stoichiometry (solid purple trace), and 1:1 stoichiometry (solid orange 
trace) for each experiment are shown. Rates constants; k1 and k-1 are expressed in M-1 




CHARACTERIZATION OF INTACT PROTEIN CONJUGATES AND BIOPHARMACEUTICALS 
USING ION-EXCHANGE CHROMATOGRAPHY WITH ONLINE DETECTION BY NATIVE 
ELECTROSPRAY IONIZATION MASS SPECTROMETRY AND TOP-DOWN TANDEM MASS 
SPECTROMETRY 
Peer-reviewed article published: Muneeruddin, K.; Nazzaro, M; Kaltashov, I.A.; Characterization 
of Intact Protein Conjugates and Biopharmaceuticals Using Ion-Exchange Chromatography with 
Online Detection by Native Electrospray Ionization Mass Spectrometry and Top-Down Tandem 
Mass Spectrometry Analytical Chemistry, 2015, 87, 10138 – 10145 
4.1. Overview 
Protein therapeutics remain the fastest growing segment in the pharmaceutical 
industry,5 and as the number of both approved biopharmaceutical products and those 
still in various development stages continue to grow, so does the demand for powerful 
and robust analytical technologies capable of comprehensive characterization of these 
complex molecules. Protein therapeutics are inherently less stable compared to 
traditional small-molecule medicines, as their large size (and, consequently, a large 
number of chemically labile sites) makes them prone to a variety of nonenzymatic post-
translational modifications (PTMs), many of which impact both therapeutic and safety 
profiles of the protein drugs. This is usually a result of conformational changes triggered 
by chemical modifications, although a loss or alteration of the higher order structure 
may also be precipitated by environmental factors, such as temperature variations and 
exposure to solvent–air interface. Therefore, complete structural characterization of 
biopharmaceutical products cannot focus solely on their covalent (primary) structure 
but must also address the higher order structure, including conformational integrity and 
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in the case of multiunit proteins correct noncovalent assembly. Demanding and 
challenging as they are, these tasks are further complicated by structural heterogeneity 
inherent to many protein-based therapeutics (e.g., due to extensive glycosylation). 
Lastly, a large number of the second-generation biopharmaceuticals contain “designer” 
modifications (such as protein–drug or protein–polymer conjugates), which increase the 
extent of heterogeneity even further due to variation in the extent of conjugation 
(loading) and the presence of multiple positional isomers within the population of 
conjugates with fixed stoichiometry. 
Obviously, comprehensive characterization of such complex systems is a very tall 
order, and analytical techniques capable of not only detecting and quantitating 
nonenzymatic PTMs within highly heterogeneous protein therapeutics but also 
assessing the impact of these modifications on conformational integrity are at premium. 
Mass spectrometry (MS) has recently emerged as a very powerful and robust tool to 
characterize biopharmaceutical products at a variety of levels ranging from mass 
profiling,92 amino acid sequencing,93, 94 and PTM mapping95-97 to conformational 
integrity20, 21, 98 and aggregation propensity.70, 99, 100 While the benefits of MS for 
comprehensive characterization of biopharmaceutical products have been well-
documented,32, 33, 101 the growing demands of characterizing ever more complex 
protein-based therapeutics continue to stimulate development of new analytical 
methodologies. Use of hyphenated techniques, such as liquid chromatography/mass 
spectrometry (LC/MS) and liquid chromatography/tandem mass spectrometry 
(LC/MS/MS), has proved particularly useful for characterization of complex protein 
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samples both in the field of biopharmaceuticals and beyond;102-104 however, the vast 
majority of applications make use of reversed-phase chromatography as the separation 
step. While the versatility of reversed-phase LC allows it to be applied for separations of 
both small peptides and large intact proteins, the nature of the mobile phase causes the 
proteins to be unfolded during the separation step. As a result, any information on the 
higher order structure (polypeptide chain folding and/or noncovalent assembly of 
multiunit protein complexes) is lost, and the MS analysis is focused exclusively on 
covalent structure. 
In contrast to reversed-phase LC, ion-exchange chromatography (IXC) and size 
exclusion chromatography (SEC) can employ nondenaturing conditions during the 
separation process, and in fact SEC is frequently used in the biopharmaceutical sector 
for assessment of the higher order structure.105, 106 IXC has also proved to be a very 
useful tool for characterization of complex biopharmaceuticals;107 however, neither of 
these two techniques is used routinely in combination with online electrospray 
ionization (ESI) MS detection. As pointed in a recent review, “while the simplicity 
associated with size exclusion and cation-exchange chromatography make them ideally 
suited for routine use, the inherent complexity of mass spectrometry restricts its use to 
characterization, this despite its richness in information.”102 Recently, we demonstrated 
that SEC/MS can in fact be used for characterization of complex biopharmaceutical 
products, yielding not only mass profiles, but also information on conformational 
integrity, aggregation propensity, and quaternary structure;87 the benefits of using 
SEC/MS for mass profiling of heterogeneous protein therapeutics have also been 
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documented.75, 108 The use of IXC with online MS detection has also been demonstrated 
recently,109 although the spray conditions in the ESI interface resulted in protein 
unfolding prior to entering MS. Consequently, all information on protein conformation 
was inferred from the chromatographic elution time,109 rather than from ESI mass 
spectra. 
In this work we present an online IXC/ESI MS in which the ESI source is operated 
under nondenaturing conditions (the so-called native ESI). Using native ESI MS as a 
detection tool allows the capability of the detector to be expanded beyond mere mass 
profiling by allowing the conformational integrity of various species to be assessed 
based on the analysis of protein ion charge state distributions in the mass spectra.110 
Furthermore, incorporation of top-down fragmentation in the experimental workflow 
(LC/MS/MS of whole proteins) allows nonenzymatic PTMs to be identified in situations 
when the mass measurement alone is not sufficient for an unequivocal conclusion to be 
reached. Although this initial report focuses on proteins of relatively modest size (not 
exceeding 25 kDa), this technique appears to be ideally suited for the analysis of large 
systems as well, including antibody–drug conjugates (ADCs) and multiunit protein 
assemblies. 
4.2. Materials and Methods 
Chicken egg white lysozyme (Lz), dithiothreitol (DTT), and iodoacetic acid (IAA) 
were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO), and N-succinimidyl-S-
acetylthioacetate (SATA) was purchased from Pierce Biotechnology (Rockford, IL). Lz 
was conjugated with SATA using a previously described procedure.111 Briefly, SATA 
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(prepared in DMSO) was added to Lz in phosphate buffer (pH 7.0) such that the ratio of 
SATA to number of primary amine sites in lysozyme was 1:1. The mixture was incubated 
at 37 °C for 90 min to allow for conjugation reaction to occur and stored at −20 °C prior 
to characterization. Complete reduction of Lz (all four disulfide bonds) was carried out 
by following a previously described procedure112, 113 that was modified to avoid 
precipitation of the (partially) reduced forms. Lz (1 mg/mL) was incubated in the 
presence of 50 mM ammonium bicarbonate (pH 8.0), 30% acetonitrile, and 20 mM DTT 
(freshly prepared in water) at 30 °C for 20 min. Following reduction, free cysteine 
residues were alkylated by adding IAA to a final concentration of 40 mM and incubating 
at room temperature for 30 min. Prior to the analyses, the pH of both freshly reduced 
and alkylated Lz solutions was adjusted to 7.0. Selective reduction and alkylation with 
IAA of a single disulfide bond, Cys6–Cys127, was carried by following the published 
protocol113 using lower DTT content (the so-called CM-lysozyme113). A stressed sample 
of raw interferon-β was provided by Biogen (Cambridge, MA). All other chemicals used 
in this work were of analytical grade or higher. 
Ion-exchange chromatography was performed on an Agilent 1100 HPLC (Agilent 
Technologies, Santa Clara, CA) equipped with a 2.1 mm × 250 mm weak cation-exchange 
column PolyCAT A (PolyLC Inc., Columbia, MD), particle size of 5 μm and pore size of 
1000 Å. Ammonium acetate at pH 7.0 was used for MS-compatible gradient elution (100 
mM in mobile phase A and 1 M mobile phase B). The total flow rate was maintained at 
0.1 mL/min (SATA-conjugated Lz and CM-lysozyme) or 0.2 mL/min (fully reduced Lz and 
stressed interferon-β1a). The specific linear gradient depended on the sample analyzed 
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(vide infra), but never exceeded 60% mobile phase B. Upon exiting the column, the 
eluate was directed to a UV absorbance detector (operated at 280 nm) followed by 
online detection by native ESI MS without any solvent modification or flow splitting 
using a QStar-XL (ABI-Sciex, Toronto, Canada) hybrid quadrupole/time-of-flight mass 
spectrometer (for the analysis of SATA-conjugated and reduced Lz) or Synapt G2Si 
(Waters, Milford, MA) hybrid quadrupole/time-of-flight mass spectrometer (for the 
analysis of stressed interferon-β). The ESI source conditions were optimized to get a 
stable spray and efficient desolvation of analyte ions. For Qstar XL the conditions were 
as follows: drying gas, 37 L/min; nebulizing gas, 30 L/min; curtain gas, 22 L/min; 
declustering potential on the skimmer, 290 V; declustering potential on the orifice, 160 
V. The source temperature was maintained in the 200–250 °C interval. For Synapt G2Si 
the conditions were optimized as follows: sampling cone, 40 V; source offset, 80 V; 
desolvation temperature, 400 °C; cone gas flow, 45 L/h; desolvation gas flow, 600 L/h. 
Online top-down fragmentation of protein ions was carried out with Synapt G2Si using 
both electron-transfer dissociation (ETD) in the trap cell and collision-induced 
dissociation (CID) in the transfer cell. For ETD the trap wave height was set at 1.0 V, and 
trap wave velocity was 300 m/s. CID was carried out by setting collision energy in the 
transfer cell to 100 and transfer gas flow rate to 4.3 mL/min. Postacquisition processing 




4.3. Results and Discussion 
4.3.1. Initial evaluation of online IXC/ESI MS: characterization of complex protein 
conjugate samples  
The utility of IXC/ESI MS for characterization of heterogeneous protein samples 
was initially evaluated using SATA-activated Lz. SATA is a short-chain reagent targeting 
primary amines, which is used to introduce a sulfhydryl group to proteins. While SATA is 
frequently used in the studies of protein higher order structure as a cross-linking 
reagent,114 our own interest in this reagent stems from its use as a coupling agent to 
produce transport protein/payload protein conjugates to enable targeted delivery.111 
Since SATA is an amine-targeting reagent, and most proteins contain at least several 
such groups (i.e., α-amine at the N-terminus and ε-amines of lysine side chains), we 
frequently observe formation of multiple conjugates, which differ in the extent of 
conjugation. Low conjugation yields result in poor efficiency of protein cross-linking, 
while extensive conjugation (placing of multiple sulfhydryls on the protein surface) leads 
to protein polymerization; hence, controlling the extent of conjugation becomes 
important, which can be readily achieved by measuring the masses of the conjugation 
products.111 However, mass measurements alone fail to characterize another dimension 
of protein conjugate heterogeneity, namely, the presence of positional isomers within 
the ensemble of protein species having identical conjugation stoichiometry. Ideally, one 
aims at producing relatively homogeneous population of conjugates (e.g., by taking 
advantage of pKa difference between α- and ε-amines and carrying out the reactions 
within the pH range where a difference in their reactivity exits), and the ability to 
 
73 
monitor protein heterogeneity due to the presence of positional isomers would 
obviously be very valuable for optimizing the conjugation protocol. 
Previously we used straightforward ESI MS to evaluate the extent of modification 
of Lz with SATA,111 while assessing the distribution of conjugation sites among seven 
possible candidates within this protein required the use of a time-consuming and labor-
intensive procedure that involves proteolytic digest and 18O labeling of fragment 
peptides followed by LC/MS and LC/MS/MS analyses (S. Nguyen et al., in preparation). 
IXC/ESI MS analysis of SATA-activated Lz at the whole-protein level (Figure 4.1) provides 
an elegant alternative by allowing both the extent of conjugation and the presence of 
positional isomers to be determined in a single experiment. While in this particular 
sample (prepared by using a 1:8 protein/SATA ratio) the extent of conjugation varies 
from 0 (intact, unmodified Lz) to 4 (SATA4·Lz), only these two species have extracted ion 
chromatograms with single peaks (52 and 30 min, respectively). The extracted ion 
chromatogram of SATA·Lz displays two major and two minor peaks (teal-filled curve in 
Figure 4.1), consistent with the notion that at least four out of seven possible amines 
participate in conjugation. The numbers of peaks in extracted ion chromatograms of 
SATA2·Lz and SATA3·Lz (six and four, respectively) are also consistent with the notion of 
four amines targeted by SATA. This relatively straightforward analysis allows a 
conclusion to be made that, while the conjugation reaction does not occur at a single 
site within the protein, the number of participating amines is limited (four out of seven). 
Importantly, this conclusion could not be made based on either chromatographic or MS 
data alone. Using ESI MS as a detection tool also allows a distinction to be readily made 
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among coeluting species with different conjugation stoichiometries (e.g., SATA·Lz and 
SATA2·Lz at 39.5 min, and SATA2·Lz and SATA3·Lz at 37 min). 
While it may be tempting to use the peak heights of various species detected in 
IXC/ESI MS analysis of the SATA/Lz conjugates for their quantitation, it should be 
remembered that the intensity of the ionic signal in ESI MS depends on a variety of 
parameters, including solvent composition115 (which is a function of time, since a 
gradual elution is used) and the presence of other coeluting species.116 Nevertheless, 
examination of the UV trace and individual extracted ion chromatograms presented in 
Figure 4.1 suggests that a reasonably good agreement exists between the UV 
absorbance and the ionic signal throughout the entire chromatogram (based on peaks 
resolved in the UV chromatogram, the deviation of relative UV and extracted ion 
chromatogram (XIC) peak intensities does not exceed 15%; see the Supporting 
Information for more information). Therefore, extracted ion chromatograms appear to 
be well-suited for at least semiquantitative assessments of relative abundances of 
various protein species present in the sample. 
4.3.2. Online IXC/ESI MS provides information on protein conformational integrity  
Above and beyond providing mass information on various protein conjugates, 
ESI MS detection allows large-scale conformational changes to be detected based on the 
analysis of protein ion charge state distributions. Mass spectra of all SATAn·Lz species 
detected in the experiment shown in Figure 4.1 are similar to each other in that only low 
charge density ions are present in the spectra (charge states ranging from +5 to +8 
populating the high m/z regions of the mass spectra). These narrow charge state 
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distributions are nearly identical to that of the intact (unconjugated) Lz (blue trace in 
Figure 4.1), suggesting that even multiply conjugated protein molecules maintain 
compact structure in solution.110  
In order to prove that large-scale unfolding can in fact be detected by IXC with 
online detection by native ESI MS, this technique was applied to characterize a mixture 
of intact Lz and fully reduced and alkylated Lz (Figure 4.2). The mixture contains only 
two species that can be readily identified based on their masses: reduction of all four 
disulfide bonds followed by alkylation of free sulfhydryls leads to a mass increase of 464 
Da (this species eluted at 15 min); no partially reduced Lz species (expected masses 
14 421, 14 537, and 14 653 Da) were observed. An important distinction between the 
two mass spectra averaged across the peaks representing fully reduced (15 min) and 
intact (43 min) Lz is the appearance of the ionic charge state distributions (inset in 
Figure 4.2): the low m/z region of the mass spectrum collected at 15 min clearly 
contains abundant ions suggesting that the protein eluted at this time undergoes 
(partial) unfolding in solution. This, of course, is not surprising, as complete reduction of 
disulfide bonds in Lz is known to compromise its higher order structure,112 which is 
reflected in the ionic charge state distribution in native ESI MS. 
In contrast to the completely reduced Lz species, removal of a single disulfide 
bond Cys6–Cys127 (which can be selectively reduced) has little effect on the structure and 
activity of native Lz.113 We used this three disulfide containing derivative of Lz (CM-
lysozyme) to demonstrate that the ionic charge state distributions do reflect protein 
conformation in solution, rather than diminished stability in the gas phase due to a loss 
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of an internal cross-link, and that IXC/ESI MS does not generate false positives regarding 
loss of protein conformational integrity. The CM-lysozyme sample in which the Cys6–
Cys127 disulfide bond was selectively reduced based on existing protocols113 was 
analyzed by IXC/ESI MS, revealing three components (Figure 4.3). These species were 
readily identified based on their masses: CM-lysozyme eluting at 36 min (mass 14 421 
Da), intact Lz eluting at 52 min (mass 14 305 Da), and a minor component eluting at 40 
min whose mass (14 363 Da) is consistent with a single alkylation event (most likely 
representing a product of a side reaction, where a fully oxidized Lz species is alkylated at 
a histidine side chain, which is known to be marginally reactive with IAA)117. Importantly, 
the ionic charge state distributions for all three detected Lz species are essentially 
identical, and no ionic signal is observed in the low m/z regions of the mass spectra (see 
inset in Figure 4.3). This is in excellent agreement with the notion of the Cys6–Cys127 
disulfide bond not being critical for the conformational stability of this protein,118 
providing additional evidence that IXC/ESI MS can be used not only for identification of 
various protein forms in complex mixtures based on their masses, but also for assessing 
their conformational integrity based on their ionic charge state distributions. 
4.3.3. Characterization of heterogeneous protein therapeutics with IXC/ESI MS and 
online protein ion top-down fragmentation: identification of stress-induced 
modifications in Interferon-β 
Evaluation of IXC/ESI MS for the analysis of complex biopharmaceutical samples 
was carried out using a stressed sample of interferon-β, a protein drug that is used for 
treatment of multiple sclerosis.119 While historically the first form of interferon-β that 
became available for clinical use was homogeneous, as it was expressed in bacteria and 
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was carbohydrate-free,120 the presence of carbohydrates is known to improve the 
activity of this protein therapeutic significantly by enhancing its stability.121, 122 Not 
surprisingly, just like many other glycoproteins, interferon-β expressed in mammalian 
cells exhibits a significant extent of heterogeneity due to the presence of multiple 
glycoforms.123 While more homogeneous preparations of this protein can be achieved 
using either extensive fractionation/purification or methods of molecular biology,124 in 
this work we intentionally used raw protein material to have the highest degree of 
heterogeneity in the analytical sample. Furthermore, the sample was stressed to induce 
nonenzymatic PTMs (deamidation) on the background of extensive enzymatic PTMs 
(glycosylation). Mass profiling of this sample carried out by ESI MS reveals the presence 
of six major glycoforms that can be distinguished from one another based on their 
masses (see inset in Figure 4.4). This number appears to agree with the number of 
partially resolved peaks observed in both UV and TIC chromatograms of the interferon-β 
sample analyzed by IXC (Figure 4.4), although the signal intensity distribution of 
chromatographic peaks does not match that of the ionic signals of different glycoforms 
in the mass spectrum of the sample prior to separation. 
The reason for this discrepancy becomes obvious when XICs are plotted for each 
of the six major glycoforms (color-fitted curves in Figure 4.4) and overlaid with the TIC. 
Intriguingly, each glycoform identified by ESI MS gives rise to two peaks in the 
chromatogram of the protein sample (e.g., the protein species whose mass is consistent 
with interferon-β bearing a BiNA2 carbohydrate chain elutes at both 17.5 and 19 min, 
and analogous behavior is exhibited by all other glycoforms). Although there must be a 
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significant difference between the two species to cause the elution time change, the 
mass measurement alone in this case is not sufficient for this difference to be identified. 
There are three nonenzymatic PTMs causing only minimal mass difference that could 
conceivably occur as a result of protein stress: disulfide reduction (mass difference 
between the intact and the modified protein 2 Da), deamidation (1 Da), and disulfide 
scrambling (0 Da). The protein mass changes caused by these PTMs are very small 
(<0.01% of the total mass) and can easily evade MS detection, while the underlying 
chemical changes might be sufficient to afford a notable change in IXC elution time. 
Since the disulfide bridge in interferon-β is important for maintaining its tertiary 
fold, its complete reduction would be expected to cause partial unfolding; a putative 
scrambling event (formation of a non-native disulfide bridge involving free cysteine 
residue at position 17) would also be expected to alter the protein conformation. At the 
same time, deamidation events125 frequently do not induce large-scale conformational 
changes.126 The charge state distributions for BiNA2 species of interferon-β eluting at 
17.5 and 19 min were nearly identical to each other, both featuring only low charge 
density ions (in the high m/z region of the mass spectra). Therefore, a conclusion was 
made that both forms of the protein maintained compact structure in solution, and the 
stress-induced nonenzymatic PTMs failed to result in large-scale conformational 
changes. While this seems to suggest that the modification in question is in fact 
deamidation, a more definitive proof was needed to unequivocally confirm the presence 
of the deamidated species in the stressed interferon-β sample. 
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In order to establish the specific nature of the stress-induced nonenzymatic PTM 
of interferon-β, an online IXC/ESI MS/MS experiment was carried out by selecting 
precursor ions within a 2480–2490 m/z window followed by ETD in the trap cell and 
collisional activation of the products in the transfer cell (see the Experimental Section 
for more detail). The ETD process was supplemented with collisional activation in order 
to facilitate physical separation of protein ion fragments in the gas phase: since the 
protein ions were generated under near-native conditions, they were expected to retain 
some higher order structure in the gas phase. This phenomenon is known to prevent 
fragment dissociation (following cleavage of a chemical bond connecting them) in many 
cases due to the presence of residual noncovalent bonds (e.g., hydrogen bonds) holding 
the two fragments together.127 Collisional heating eliminates these residual bonds and 
facilitates the dissociation process.127 The fragmentation patterns obtained for both 
species of interferon-β (see the Supporting Information) are nearly identical to each 
other and feature abundant fragments within the Met1–Tyr30 and Ala142–Asn156 
segments of the protein. The near absence of fragments due to backbone cleavages in 
the protein segment flanked by Cys31 and Cys141 suggests that the disulfide bond 
connecting them is intact in both forms of the protein and rules out both disulfide 
scrambling and complete reduction as stress outcomes. 
There is only one additional ion that is present in the fragmentation spectrum 
averaged across the earlier-eluting peak of the BiNA2 species of interferon-β, namely, 
b252+; the only other difference between the two sets of fragment ions is the 1 Da mass 
shift for the c302+ ion recorded at earlier elution time (see insets in Figure 4.5). The 
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protein segment covered by the latter fragment incorporates an asparagine residue 
(Asn25), and deamidation at that position would indeed result in a mass increase of 1 Da, 
which is reflected in the mass shift of c302+. Furthermore, deamidation at this position 
would create a proximal acid–basic residue pair (Asp25Gly26Arg27), a motif known to 
facilitate a direct bond cleavage of the amide bond adjacent to the aspartic acid 
residue,128 hence the appearance of the b252+ fragment in the spectrum averaged across 
the earlier-eluting peak. We also note that the monoisotopic mass of the b252+ fragment 
is 1 Da higher compared to the theoretical mass of this fragment calculated based on 
the sequence of intact interferon-β (and, therefore, consistent with a single 
deamidation event occurring within the N-terminal segment of the protein). Taken 
together, these observations not only provide unequivocal evidence that the 
nonenzymatic PTM triggered by stress is indeed deamidation, but also allow the 
affected site to be localized within the protein sequence. While there is a variety of 
mass spectrometry-based methods to detect protein deamidation and localize the 
affected sites,129, 130 a top-down approach to this task offers multiple advantages, such 
as elimination of additional sample preparation steps (enzymatic digestion and 
separation of peptide fragments).130 In addition to decreasing the analysis time to less 
than 1 h, it also eliminates artifacts that could occur during sample preparation required 
for bottom-up analysis.129 However, until recently the top-down approach was applied 
only to small carbohydrate-free proteins. Combining top-down fragmentation with IXC 
and online native ESI MS expands the capability of this technique dramatically by 




Online LC/MS and LC/MS/MS analysis of proteins and related macromolecules 
has long been a workhorse in many fields of bioanalysis, including the 
biopharmaceutical sector. Although the majority of applications make use of reversed-
phase chromatography, other modes of separation are also actively evaluated. Of 
particular interest are methods that do not trigger protein denaturation during the 
separation step, as they enable analysis of not only covalent (primary) structure, but 
also higher order structure (including conformation and quaternary assembly). IXC is 
shown in this work to be a very attractive candidate for these analyses, as it can be 
applied to a wide range of challenging targets of interest to biopharmaceutical and 
biotechnology sectors, can be operated under conditions that do not disrupt protein 
higher order structure, and can be interfaced with native ESI MS. The latter provides 
information on both identity of components of protein-based products (by measuring 
masses) and their conformational integrity (via analysis of ionic charge state 
distributions), while the former allows isomers (as well as isoforms with nearly 
indistinguishable masses) to be separated. Incorporation of the top-down fragmentation 
step in the IXC/ESI MS workflow allows stress-induced nonenzymatic PTMs to be 
detected and localized in very complex and heterogeneous samples on the background 
of extensive enzymatic PTMs, such as glycosylation. Although the size of the largest 
protein therapeutic interrogated using the new IXC/ESI MS method in this work is 
relatively modest (23 kDa), a work is currently underway in our laboratory to expand the 
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reach of this new methodology to significantly larger and more heterogeneous targets, 



































Figure 4.1 IXC/ESI MS analysis of a mixture of SATA-conjugated Lz: a UV chromatogram, a total 
ion chromatogram, and extracted ion chromatograms for unmodified Lz and conjugates with 
different loadings (left panel) and ESI mass spectra (right panel) averaged across 
chromatographic peaks as indicated with colored dots on the chromatogram. The inset shows 
zoomed views of charge states +7 (note that the top spectrum contains ionic contributions from 
both SATA2·Lz and SATA3·Lz). The total amount of injected protein was 0.1 mg. The arrow 










Figure 4.2 IXC/ESI MS analysis of a mixture of intact (fully oxidized) Lz and a fully reduced and 
alkylated Lz: a UV chromatogram (gray trace), a TIC chromatogram (black trace), and extracted 
ion chromatograms for ions representing the fully reduced (red) and intact Lz (blue). The inset 












Figure 4.3 IXC/ESI MS analysis of Lz following selective reduction of a single disulfide bond: a UV 
chromatogram (gray trace), a TIC chromatogram (black trace), and extracted ion 
chromatograms for ions representing the species with three disulfide bonds (red), oxidized 
intact (blue), and oxidized singly alkylated Lz (purple). The inset shows mass spectra averaged 









Figure 4.4 IXC/ESI MS analysis of stressed interferon-β sample: TIC chromatogram and extracted 
ion chromatograms of seven different glycoforms identified in the mass spectrum of the protein 
sample not subjected to separation (shown in inset). The carbohydrate chain structures were 
assigned based on measured mass and are also shown in the inset (structure key: squares, 
GlcNac residues; triangles, fucose residues; open circles, mannose residues; filled circles, 










Figure 4.5 Identification and localization of a stress-induced nonenzymatic PTM within the BiNA2 
species of interferon-β by IXC/ESI MS/MS: TIC for all fragment ions produced by ETD and 
collisional activation of precursor ions corresponding to the +9 charge state of the BiNA2 species 
(black trace) and extracted ion chromatograms corresponding to two different isotopic peaks 
within the c302+ fragment ion (blue, m/z 1826.9; red, m/z 1825.4). The insets on the left show 
isotopic distributions of fragment ions that are observed in both chromatographic peaks (c302+ 
and y172+) and unique to the earlier-eluting species (b252+). The inset on the right shows overall 






Table S.1.Relative signal intensities of SATAnLz conjugates from UV chromatogram and XIC’s 









52.0 100 100 
50.1 99.7 88.2 
48.1 28.6 29.4 
46.9 23.1 23.5 
45.1 15.3 17.6 
42.1 73.0 63.5 
 
 
Figure S6. Top-down fragmentation patterns observed for interferon-β species eluting at 




CHARACTERIZATION OF PEGYLATED-PROTEIN CONJUGATES BY WEAK CATION 
EXCHANGE CHROMATOGRAPHY WITH ONLINE DETECTION BY NATIVE ESI MS 
SUPPLEMENTED WITH GAS PHASE REACTIONS 
5.1. Overview 
Covalent attachment of poly ethylene glycol (PEG) to proteins has demonstrated 
to be the most successful approach to improve pharmacokinetic and pharmacodynamics 
profile of protein drugs.131 PEGylation increases the efficacy of protein drugs by 
improving solubility, stability over wide pH and temperature range, decreasing renal 
clearance, and limiting toxicity and immunogenicity.132 All of these eventually contribute 
to less frequent administration of PEGylated protein drug to achieve the same 
therapeutic outcome as its non-PEGylated form. However, due to polydispersity of PEG 
molecule, PEGylation of protein increases complexity of the sample making its analytical 
characterization very challenging. 
Structural heterogeneity of PEGylated proteins occurs due to the presence of 
complex species differing in the number of PEG chains conjugated, sites of conjugation, 
and lengths of PEG chains. Many analytical methods have been reported to analyze the 
presence of positional isomers in PEGylated proteins, some of these involved enzymatic 
treatment to leave behind chemical tags to identify site of conjugation,133 use of new 
PEG derivatives,134 and using chromatographic separation followed by top-down MS 
analysis.135 Strategies have also been reported for site specific conjugation of proteins 
with PEG.9, 136 Apart from heterogeneity due to PEG chain, an additional level of 
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complexity could arise in PEGylated proteins due to the presence of enzymatic post 
translational modifications (e.g., glycosylation) or non-enzymatic post translational 
modifications (e.g., oxidation, deamidation). 
Electrospray ionization mass spectrometry (ESI MS) has demonstrated to be very 
useful for structural characterization of biopharmaceutical products.32 While native ESI 
MS has been particularly useful as a tool of providing information on mass, 
conformational integrity and interactions of protein drugs, it often fails for highly 
heterogeneous samples (e.g., PEGylated proteins for reasons mentioned in the 
preceding paragraphs). To analyze such samples ESI MS supplemented with limited 
charge reduction introduced by our lab has shown a lot of potential, and has indeed 
been applied to analyze highly glycosylated proteins and their complexes, and soluble 
protein aggregates.70, 137 In chapters 2 and 4 native ESI MS based methods have also 
been presented in which chromatographic separation of various protein species by size 
exclusion chromatography or ion exchange chromatography (IXC) helped in the analysis 
of protein heterogeneity. 
IXC is also helpful in the analysis of PEGylated proteins; a method was reported 
from our lab by combining separation capabilities of IXC and top-down tandem MS to 
monitor positional isomers and map PEGylation sites on a 8.6 kDa ubiquitin protein 
conjugated with 5kDa PEG chain.135 It also presented important fundamental aspects to 
reduce the complexity of mass spectrum (related to polydispersity of PEG) using 
collisional activated dissociation (CAD). In this work a new analytical strategy by 
combining ion exchange chromatography with online native ESI MS detection is 
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presented to analyze proteins conjugated with larger PEG chain. Limited charge 
reduction (LCR) or CAD is implemented in online LC/MS mode for characterization of 
PEGylation stoichiometry and different post translational modifications. This strategy 
have been applied to a complex mixture containing 22 kDa glycoprotein conjugated with 
a 20kDa PEG chain. 
5.2. Materials and Methods 
Stressed (partially deamidated) sample of PEGylated glycoprotein was provided 
by Biogen (Cambridge, MA). All other chemicals used in this work were of analytical 
grade or higher. Online IXC/MS analysis of stressed PEGylated glycoprotein was carried 
out directly by diluting the sample in 100 mM ammonium acetate, pH 5.5 to a required 
concentration. 
Ion-exchange chromatography was performed on an Agilent 1100 HPLC (Agilent 
Technologies, Santa Clara, CA) equipped with a 2 mm × 250 mm weak cation-exchange 
column ProPac WCX-10 (Thermo Scientific Waltham, MA). Ammonium acetate at pH 5.5 
was used for MS-compatible gradient elution (100 mM in mobile phase A and 1 M 
mobile phase B). The total flow rate was maintained at 0.2 mL/minute. Linear gradient 
reaching 25% B over 50 minutes after equilibration with mobile phase A for 3 minutes 
was used. Concentration of PEGylated glycoprotein used was 1mg/ml and was injected 
using a 20 µl sample loop. Upon exiting the column, the eluate was directed to online 
detection by native ESI MS without any solvent modification or flow splitting using 
Synapt G2Si (Waters, Milford, MA) hybrid quadrupole/time-of-flight mass spectrometer. 
LCR was carried using electron transfer dissociation (ETD) on narrow population of ions 
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isolated at m/z 1150 with 10 m/z isolation window. The conditions were optimized as 
follows: capillary voltage, 2.5 kV, sampling cone, 5.0 V; source offset, 80 V; desolvation 
temperature, 400 °C; source temperature, 120 °C, cone gas flow, 45 L/h; desolvation gas 
flow, 600 L/h; make up gas flow, 35L/h; trap gas, 33.0 ml/min; transfer gas, 0.8 ml/min; 
trap wave height, 0.08 V. CAD was carried out on ions isolated at m/z 1050 using 10 m/z 
window in transfer cell by setting the collision energy at 25.0V and transfer gas to 2.0 
ml/min. 
5.3. Results and Discussion 
Separation of this stressed PEGylated glycoprotein by WCX yielded four partially 
resolved peaks along with an inflection point at 27-28 minutes interval (figure 5.1). The 
species resolved by WCX could represent positional isomers and species with different 
number of PEG chains conjugated to protein. In the case of this protein the presence of 
positional isomers can be ruled out as PEGylation chemistry was optimized to conjugate 
specifically at N terminal. However extensive heterogeneity due to the presence of 
various glycoforms and deamidated forms could also lead to occurrence of different 
PEGylated species. All these factors contributing to heterogeneity along with multiple 
ESI MS charge states resulted in completely unresolved mass spectra detected for all of 
the WCX peaks as shown in the upper right panel of figure 5.1. These mass spectra imply 
occurrence of ion at each m/z in 800 – 1400 m/z range. 
To analyze this sample LCR using ETD in the online WCX/ESI MS mode was 
implemented. For the entire duration of LC, LCR was carried out on a narrow population 
of ions isolated at m/z 1150. Charge state ladder resulting from this experiment enabled 
 
93 
detection of the mass of isolated ions. In the bottom right panel of figure 5.1, a mass 
spectrum obtained by averaging ESI MS LCR scans for ions (m/z 1150) eluting at 30 – 32 
minutes is shown. Deconvolution of this mass spectrum gave a mass of ~45 kDa, which 
is in agreement with 1:1 PEGylation of glycoprotein taking into account molecular 
weight distribution of 20kDa PEG chain and molecular weight of this glycoprotein 
(22kDa). ESI MS LCR data of m/z 1150 ions detected from other WCX peaks also gave 
identical charge ladder deconvoluting to a mass consistent with 1:1 PEGylation 
stoichiometry. This way by using LCR in conjunction with WCX/ESI MS, detection of 
PEGylation stoichiometry was made possible, and all the stressed PEGylated 
glycoprotein species resolved partially by WCX (figure 5.1) were found to be conjugated 
with one chain of PEG. Unfortunately due to continuum of mass and broad LCR peaks 
we were not able to differentiate various glycoforms. 
For further analysis of this sample, a WCX/online ESI MS method was developed 
in which CAD was applied to a narrow population of ions at m/z 1050 (isolated over 
entire LC timescale). As seen in figure 5.2 the complexity of mass spectrum is decreased 
significantly leading to detection of clusters of distinguishable ionic peaks. Charge state 
assignment for each of these ionic clusters was carried out easily by dividing the 
adjacent peak spacing with the repeating mass of PEG unit (44 u). The mass of these 
ions correspond to cleavage of PEG chains following the route that produces B and C 
ions as proposed by Lattimer and his colleagues.138 Similar ions were also produced, 
when insource CAD was applied to PEGylated Ubiquitin as reported in the work carried 
out previously in our lab.135 CAD conditions were optimized to cleave most of the PEG 
 
94 
chain keeping the polypeptide backbone of the glycoprotein intact (figure 5.2).  Multiply 
charged ion clusters corresponding to six PEG molecules bound to intact glycoprotein 
(B6+14 - B6+10 ions) were detected. These features led to simplified mass spectra enabling 
identification of different stressed PEGylated glycoforms present in the sample as they 
are separated by WCX (see right panel of figure 5.2). 
Careful analysis of this data revealed the presence of PEGylated species bearing 
BiNA2, TriNA3, BiNA1, and TriLACNA3 carbohydrates (see figures 5.3 and 5.4). Mass 
spectrum correlating with PEG BiNA2 glycoforms was recorded in two chromatographic 
peaks eluting at 28.2 – 29.3 and 31.9 – 33.5 minutes interval. Similarly based on ESI MS 
mass measurements TriNA3 was found to elute at 25.0 – 28.0 and 30.0 – 31.4 minutes 
interval. Identification of these glycoforms based on mass was further confirmed by 
detection of fragment ions produced from cleavage of terminal carbohydrate chain 
residues (sialic acid). As shown in figure 5.3, in addition to intact BiNA2 ion mass spectra 
detected at 28.2 – 29.3 and 31.9 – 33.5 minutes  also showed ions whose mass was 
consistent with loss of one and two sialic acids. BiNA1 was confirmed to elute in the last 
chromatographic peak based on mass and detection of fragment ions from loss of only 
one sialic acid residue. Similarly TriNA3 glycoform (figure 5.4) showed ions from 
fragmentation of up to 3 sialic acids. Though BiNA1 ion seen in figure 5.4 could be due 
to fragmentation of GlcNAc and galactose units from TriNA2 form, it most likely appears 
in this mass spectrum due to tailing of chromatographic peak (see extracted ion 
chromatogram, XIC in figure 5.5). 
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XIC plotted in a straightforward way using the corresponding ions led to an 
artificial increase in XIC peak signal due to absence of baseline resolved mass spectra 
(see mass spectra in figure 5.2). To eliminate this noise, XICs were produced by 
subtracting ionic intensities of the two most abundant peaks belonging to the same 
cluster of glycoform ions (e.g., XIC of BiNA2 glycoform using the BiNA1 fragment ions 
was made by subtracting XIC’s abundance of 2033.0 and 2037.6 m/z ions). It is not 
surprising to see the presence of two chromatographic peaks for each glycoform (BiNA2 
and TriNA3) of this stressed PEGylated glycoprotein; a similar observation was made in 
chapter 3 when interferon was analyzed by WCX/ESI MS. Therefore the earlier eluting 
chromatographic peaks of each glycoform most likely represent PEGylated deamidated 
fraction of TriNA3 and BiNA2. 
5.4. Conclusions 
Growing trend of heterogeneity in biopharmaceuticals occurring either naturally 
or induced by chemical modification (PEGylation in this work) presents a serious 
challenge to analytical characterization. In this chapter analytical strategy has been 
presented, which combined chromatographic separation along with various gas phase 
chemistry techniques (ETD, CAD) in ESI MS. WCX separation has proved to be very 
powerful in delineating the presence of non-enzymatic PTM (deamidation) on intact 
protein glycoforms, which is not possible using bottom-up MS approach or standard 
RPLC/MS. The feasibility of carrying out these kinds of gas phase measurements in 
online mode helps by decreasing the analysis time, and also illustrates a novel method 
to analyze such highly heterogeneous samples. Interfacing WCX/ESI MS with LCR has 
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been demonstrated to be suitable for characterization of stoichiometry of PEGylated 
sample. This WCX/MS LCR workflow can also be used for characterization of non-
covalent protein complexes involving such PEGylated proteins. For a thorough 
characterization of PEGylated proteins implementing CAD just enough to cleave most of 
the PEG chain has shown to be a promising approach to reduce complexity of mass 

























Figure 5.1 IXC/ESI MS analysis of stressed PEGylated glycoprotein: total ion chromatogram (TIC) 
shown in black trace (lower left panel) and the upper right panel shows mass spectra averaged 
across the correspnding chromatographic peaks marked with same colored circles. Lower right 
panel is from IXC ESI MS LCR analysis; charge state ladder detected for the isolated ions (m/z 
1150) of chromatographic peak marked with green circle. LCR charge state ladders for the ions 










Figure 5.2 IXC/ESI MS CAD analysis of stressed PEGylated glycoprotein: a total ion 
chromatogram (TIC) obtained from CAD of ions isolated at m/z 1050 is shown in black trace 
(lower left panel) and the right panel shows mass spectra averaged across each 
chromatographic peak. BiNA2 glycoform eluted at 28.2 - 29.3  and 31.9 - 33.5 minutes; TriNA2 
and TriLACNA2 glycoforms at 25.0 - 28.0 and 30 .0 – 31.4 minutes; BiNA1 glycoform at 36.0 - 








Figure 5.3 Zoom of +11 charge state of the mass spectra detected from IXC/ESI MS CAD of 
stressed PEGylated glycoprotein. The carbohydrate ions were assigned based on measured 
mass after subtraction of 6 PEG units’ mass. (structure key: squares, GlcNac residues; triangles, 
fucose residues; open circles, mannose residues; filled circles, galactose residues; diamonds, 
sialic acid residues). BiNA2 glycoform was detected in peaks eluting at 28.2 – 29.3 and 31.9 – 








Figure 5.4 Zoom of +11 charge state of the mass spectra detected from IXC/ESI MS CAD of 
stressed PEGylated glycoprotein. These mass spectra correspond to ions detected in TriNA3 
glycoform. Ions marked with asterisk correspond to TriLACNA3. BiNA1 and BiNA0 glycoform 
fragment ions are observed due to tailing of BiNA2 glycoform. The carbohydrate ions were 
assigned based on measured mass after subtraction of 6 PEG units’ mass. (structure key: squares, 
GlcNac residues; triangles, fucose residues; open circles, mannose residues; filled circles, 










Figure 5.5 Extracted ion chromatograms (XICs) of BiNA2 and TriNA3 PEGylated glycoforms 
detected from WCX/ESI MS CAD analysis. XIC of BiNA2 glycoform was made using BiNA1 




CONCLUSIONS AND FUTURE OUTLOOK 
Novel analytical methods combining non-denaturing liquid chromatography 
separation with native ESI MS detection were developed in this work. These methods 
have applications in characterization of biopolymer structure and interaction to help in 
the development and quality control of biotherapeutics. 
SEC with online native ESI MS detection method developed in chapter 2 allowed 
characterization of higher order structure of proteins. It was shown to be useful in 
probing conformational integrity and detection of soluble protein aggregates of a model 
protein (bovine serum albumin), and characterize rapidly interconverting oligomeric 
states of a recombinant glycoprotein human arylsulfatase A.  
Using the same SEC/ESI MS workflow a method to measure kinetics and binding 
affinity of transient protein interactions have also been developed. This method 
involved fitting of experimental XICs with the profile generated using mathematical 
solutions. Validation of this new method for analysis of protein interactions with 1:1 and 
2:1 binding stoichiometry was carried out using the known binding of C-lobe of human 
transferrin and transferrin variants, respectively with human transferrin receptor. 
Further validation of this method will be carried out by changing the concentration of 
interacting proteins, which will change binding kinetics, but should give the same 
equilibrium dissociation constant. This method has significant potential as it does not 
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require immobilization or labelling of proteins, works with small amount of sample, and 
could be applied for complexes interacting with higher stoichiometries.  
 
Combination of IXC with online native ESI MS detection was developed and 
shown to be effective in characterization of conformational integrity and positional 
isomers of protein conjugates (using chemically modified lysozyme as a model) and 
PTMs of a biotherapeutic recombinant human interferon beta 1a. Top-down 
fragmentation in this workflow (IXC/MS/MS of whole proteins) allowed non-enzymatic 
PTMs to be identified in situations when the mass measurement alone was not 
sufficient for an unequivocal conclusion to be reached. To characterize highly 
heterogeneous PEGylated glycoprotein IXC/online ESI MS methods supplemented with 
gas phase reactions (limited charge reduction and collisional activation) were 
developed. These methods allowed detection of PEGylation stoichiometry and 
glycoform distribution of intact PEGylated protein. A prerequisite for methods 
developed in chapter 2 – 4 is that separation needs to be carried out in MS friendly 
volatile mobile phase. 
Separation by SEC applies for systems containing globular proteins, however it is 
most likely to fail for complexes containing non-globular biopolymers (e.g., 
protein/DNA, protein/glycosaminoglycans), where differences in hydrodynamic radii is 
not significant to allow separation based on size. To characterize transient complexes 
containing such species, other modes of non-denaturing chromatography will be 
implemented. IXC with online ESI MS detection will be particularly useful in this 
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situation. Fitting XICs detected in IXC/ESI MS with the ADR equations similar to those 
developed in chapter 3, kinetics and binding affinity of the complexes can be measured. 
Unlike size filtration in SEC, linear velocities in IXC will depend on the interaction of the 
species with the charged resin. This method will be applied for characterization of 
protein/DNA complexes, which plays an important role in gene regulation. 
The feasibility of carrying out limited charge reduction in online LC/MS opens 
exciting opportunities. Implementing this feature in the SEC/ESI MS method developed 
in chapter 3 and in IXC/ESI MS will enable qualitative analysis of interaction of highly 
heterogeneous biopolymers and to measure kinetics and binding affinity. Transient 
complexes that will be characterized using these methods include highly glycosylated 
proteins (e.g., hemoglobin-drug conjugate binding to haptoglobin), protein-polymer 














APPENDIX TO CHAPTER 3 
Derivation of partial derivative equation for rhASA (chapter 3) 
Assuming a short lived intermediate tetramer (M4); M2 ⇌ M8 transition of rhASA can 
be understood by the following rate equation80 
2𝑀2 ⇌𝑘−2 (𝑓𝑟𝑑𝑓)
𝑘2 (𝑑𝑠𝑠𝑠) 𝑀4;  2𝑀4 ⇌𝑘−4 (𝑑𝑠𝑠𝑠)
𝑘4 (𝑓𝑟𝑑𝑓) 𝑀8                                                                                (1)               
The cumulative rates of octamer production and loss under steady state condition will 
be  
𝑅𝑑𝑑𝑑𝑑𝑠𝑑= 𝑘−4𝐶𝑀8; 𝑅𝑟𝑑𝑑𝑠𝑑= 
1
2
𝑘2𝐶𝑀22                                                                                               (2)                                    
Concentration of M8 at any point x across the column length (0 < x < L) will also be 
affected by longitudinal transfer and diffusion. 
 
Mass transfer will be characterized by hydrodynamic flux through column cross-section 
S. Hydrodynamic flux (JM8) of M8 depends on the linear velocity (uM8) and concentration 
gradient (CM8) 
𝐽𝑀8(𝜕, 𝑡) =  𝑢𝑀8· 𝐶𝑀8(x, t)              (3)                                                    
Diffusion is determined by diffusion coefficient (DM8) and concentration gradient for M8 
𝐽𝑀8(𝜕, 𝑡) =  −𝐷𝑀8  ·  
𝜕 𝐶𝑀8(𝑥,𝑓)
𝜕𝑥
                                                                                                 (4)                                           
Total change of the number of M8 molecules within the infinitely small slice of the 
column volume (S.δx) over an infinitely small period of time δt will reflect a difference 
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between the rates of association and dissociation, as well as the difference between the 
incoming flux of M8 and the outgoing flux  
𝛿𝐶𝑀8 · 𝑆𝛿𝜕 = −𝑆 · 𝑢𝑀8 · 𝛿𝐶𝑀8 · 𝛿𝑡 + 𝑆 · 𝐷𝑀8 · 𝛿 �
𝜕𝐶𝑀8(𝜕, 𝑡)
𝜕𝜕
� · 𝛿𝑡 − 𝑆𝛿𝜕 · 𝑅𝑑𝑑𝑑𝑑𝑠𝑑 · 𝛿𝑡 + 𝑆𝛿𝜕
· 𝑅𝑟𝑑𝑑𝑠𝑑 · 𝛿𝑡                                                                                                                          (5) 
Association and dissociation terms are defined by eq.2. Since x and t are independent 
variables, eq. 5 can be re-written in the form of a partial differential equation, and a 



























+ 4𝑘−4𝐶𝑀8 − 2𝑘2𝐶𝑀22
                                                (6) 
List of parameters used in the calculations of partial differential equations for FeTfC 
and TfR interaction 
uP = 1.465 cm/min 
uR = 1.740 cm/min 
uPR = 1.845 cm/min 
DP = 0.0027cm2/min 
DR = 0.0134 cm2/min 
DPR = 0.0122cm2/min 
List of parameters used in the calculations of partial differential equations for hTf and 
TfR interaction 
uP = 1.71 cm/min 
uR = 1.74 cm/min 
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uPR = 1.87 cm/min 
uP2R = 2.08 cm/min 
DP = 0.0026 cm2/min 
DR = 0.0134 cm2/min 
DPR = 0.0110 cm2/min 
DP2R = 0.0090 cm2/min 
List of parameters used in the calculations of partial differential equations for Fe2 bTf 
and TfR interaction 
uP = 1.67 cm/min 
uR = 1.74 cm/min 
uPR = 1.80 cm/min 
uP2R = 2.00 cm/min 
DP = 0.0026 cm2/min 
DR = 0.0134 cm2/min 
DPR = 0.0110 cm2/min 
DP2R = 0.0090 cm2/min 
List of parameters used in the calculations of partial differential equations for bTf and 
TfR interaction 
uP = 1.70 cm/min 
uR = 1.74 cm/min 
uPR = 1.87 cm/min 
uP2R = 2.08 cm/min 
DP = 0.0026 cm2/min 
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DR = 0.0134 cm2/min 
DPR = 0.0110 cm2/min 
DP2R = 0.0090 cm2/min 
Initial (injection) concentrations of all the components were represented as boxcar 
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